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CHAPTER I 
 
 
INTRODUCTION 
 
 
Clostridium difficile 
 
 Clostridium difficile is a Gram positive, spore-forming, anaerobic bacterium that is 
commonly found in the soil and can also colonize the colon of many mammals, 
including humans and livestock.  C. difficile was discovered in 1935 when Ivan Hall and 
Elizabeth O’Toole isolated the bacteria from the stool of healthy infants [7].  C. difficile 
remained a poorly understood organism for many years, considered part of the normal 
flora of infants.  Today, C. difficile is known as one of the most threatening nosocomial 
pathogens, making the mechanisms of pathogenesis important areas of investigation.  
C. difficile is an opportunistic bacterium as it is usually outcompeted by normal intestinal 
bacteria.  Infection typically occurs after a perturbation, most often broad spectrum 
antibiotics, to the colon and its normal, healthy flora.  C. difficile is inherently resistant to 
many commonly used antibiotics, including erythromycin, clindamycin, tetracycline, and 
moxifloxacin, allowing it to flourish in the absence of its non-resistant competitors [9].  
Once C. difficile has colonized the colon, it can, like many Clostridia species, secrete 
large exotoxins that cause disease symptoms collectively known as Clostridium difficile 
infection (CDI). 
 
 
Clostridium difficile Infection 
 
Epidemiology 
 C. difficile is the most common cause of nosocomial diarrhea and was classified 
as one of the most urgent threats to patient health in 2013 by the Center for Disease 
Control with almost 500,000 infections and more than 29,000 deaths in 2011 [12].  Both 
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prevalence and mortality rates have more than doubled since 2007.  Though a very 
small percentage of the population (3%) is asymptomatically colonized, most C. difficile 
infections occur in health care facilities [13,14].  An average of 30% of patients test 
positive for C. difficile at a given time in healthcare facilities across the country.  It 
should be noted that prevalence and incidence vary drastically based on both 
geographic and demographic factors [9].  High incidence and easy transmission of the 
bacteria in hospitals and nursing homes is attributed to the production of hardy and 
resilient spores and the emergence of an epidemic strain, NAP1/027.  Because spores 
are resistant to most cleaning solutions, an estimated 20-43% of hospital surfaces are 
contaminated, leading to overwhelming infection rates [9].  One study showed that of 
399 patients testing negative for C. difficile upon admittance to the hospital, 21% tested 
positive for colonization over the course of their hospital stay.  While most of these 
patients remained asymptomatic (63%), 37% developed CDI symptoms [15].  The 
NAP1/027 strain is thought to contribute to increased incidence and also more severe 
disease, with an overall mortality rate of 17% [9].  The epidemic strain has been shown 
to have increased toxin production [16], higher rates of sporulation [17,18], and 
increased antibiotic resistance [19].   
Major risk factors for developing CDI symptoms have been identified as antibiotic 
therapy, advanced age (≥ 65 years), renal insufficiency, immunosuppression, 
comorbidities, presence of nasogastric tubes, recent gastrointestinal procedures, use of 
proton pump inhibitors, ICU admission, and duration of hospital stay [20].  The most 
understood of these is prior antibiotic therapy.  An average of 96% of all CDI patients 
were on antibiotic therapy prior to the manifestation of symptoms [9].  The length of 
hospitalization is another well documented risk factor.  Patients hospitalized for more 
than one week had a 15-45% chance of acquiring CDI, according to one study [21].  
The opposite correlation is also well documented.  CDI has been shown to lengthen 
hospital stays by an average 4-5 days, increasing costs of each stay by an additional 
$2,000-$14,000 [22,23].  CDI presents a significant burden to the United States 
healthcare system which has been estimated to surpass $4.8 billion each year [24-26]. 
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Symptoms 
 C. difficile is most commonly ingested in the form of spores which can germinate 
in the duodenum in response to bile salts.  The mechanisms of sporulation and 
germination are not well understood, though glycine and taurocholic acid have been 
implicated as components of bile that can initiate germination [27].  Colonization of the 
colon and risk of infection are greatly increased in patients that have received antibiotic 
therapy.  Virtually every antibiotic has been associated with CDI.  Clindamycin, 
fluoroquinolones, penicillins, and cephalosporins are commonly associated with and 
considered risk factors for developing symptomatic CDI [28-31].  Disease symptoms 
typically appear 4-9 days into antibiotic treatment and can span a wide range of 
disorders from diarrhea to potentially lethal fulminant colitis and toxic megacolon [32].  
The most common symptoms include diarrhea, crampy abdominal pain, fever, and 
leukocytosis [32].  Pseudomembraneous colitis (PMC) is the most common 
complication of CDI [33].  PMC is described as severe inflammation accompanied by 
raised plaques (pseudomembranes) along the colonic mucosa.  The plaques are 
usually small in size and contain fibrin, mucin, necrotic epithelial cells, and dead 
neutrophils [34].  Although rare, severe cases of CDI are described as fulminant colitis 
and/or toxic megacolon and are increasing in incidence (3-8% and 0.3-4%, respectively) 
[9,35].  These complications are often difficult to diagnose because of their sudden 
onset and consequently have alarmingly high death rates associated with their 
occurrence (30-90% and 38-80%, respectively).  An estimated 20% of fulminant colitis 
patients present with abdominal pain in the absence of diarrhea [32].  Similarly, toxic 
megacolon is a condition in which the colon becomes paralyzed, ceasing peristalsis, 
and alleviating diarrheal symptoms.  This allows for the accumulation of digestive gases 
leading to extreme dilation and swelling of the colon.  Toxic megacolon can lead to 
bowel perforation and multi-organ failure, often resulting in death [33].   
 
Diagnosis  
 There are many tests available to determine whether or not a patient is infected 
with C. difficile.  The gold standard is a cell cytotoxin assay in which stool filtrate is 
applied directly to tissue culture cells and assessed for cytopathic effects (CPE) in 24 to 
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48 hours.  This test is considered to be both sensitive and specific though quite time 
consuming.  Several enzyme-linked immunosorbent assays (ELISA) have been 
developed for the detection of toxins secreted by C. difficile in stool. These are very 
specific but lack sensitivity.  The return time for these assays can be as short as 6 
hours, but there is a risk of false-negatives.  C. difficile can also be cultured from the 
stool of infected patients.  Though the turnaround time is quite long (2-5 days), this 
method of testing is specific, sensitive, and allows strain identification.  Polymerase 
chain reaction (PCR) to detect the presence of toxin genes is another very sensitive and 
specific diagnostic test.  This test is more expensive than others and can detect the 
presence of C. difficile in asymptomatic patients.  Latex agglutination assays, which 
detect the presence of glutamate dehydrogenase, are also used to diagnose C. difficile 
because they are quick, easy, and inexpensive.  This test, however, is not specific or 
sensitive to the presence of pathogenic C. difficile [9,33]. 
 In addition to biochemical and microbiological tests, computed tomography (CT) 
scans are often used to rule out other causes of abdominal pain and to assess the 
severity of disease.  Endoscopy is used to assess the colonic mucosa and diagnose 
pseudomembranous colitis.  This procedure also allows the collection of stool samples 
for further testing.  Most diagnostic guidelines discourage the use of a single test for 
accurate diagnoses [9,33].   
 
Treatment 
 Upon CDI diagnosis, the preferred course of treatment includes stopping the 
initial antibiotic therapy and beginning oral metronidazole in cases of mild to moderate 
CDI.  Symptoms resolve within 10 days in approximately 60% of patients. Metronidazole 
is preferred to vancomycin because of its lower cost and reduced risk of selecting for 
vancomycin-resistant entercocci (VRE).  Metronidazole, however, has been reported to 
have a higher failure and recurrence rate than vancomycin.  Vancomycin and early 
surgical intervention are recommended for the treatment of severe or complicated CDI.  
Subtotal or total colectomy is often required and can reduce mortality rates [9,33]. 
 Some alternative treatments are proving to be quite effective.  Fidaxomicin was 
approved for use as a CDI therapy in 2011, and has since been shown to be noninferior 
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to vancomycin in terms of cure rates and led to fewer recurrent infections than 
vancomycin in a number of studies [36-39].  Fidaxomicin is a particularly useful 
therapeutic in cases where the original antibiotic cannot be discontinued [40].  It is fairly 
specific to C. difficile and thought to be significantly less disruptive to the normal gut 
microbiota, making it a good option for the treatment of recurrent CDI [41-43].  Although 
considered investigational by the US Food and Drug Administration (FDA), fecal 
microbiota transplants have been effective in the treatment and prevention of recurrent 
CDI [44-46].  In this procedure, stool from a healthy donor is instilled in the 
gastrointestinal tract of a patient with CDI, thus replenishing the healthy, diverse 
microbiota that normally outcompete C. difficile [44].  In 2013, purified bacteria were 
lyophilized into pill form as “synthetic stool” as a more appealing alternative to fecal 
transplants.  Limited data show some success with the synthetic stool in patients not 
responding to antibiotics [47]. 
 Even less data support the use of other antibiotics (rifaximin, nitazoxinide, and 
tigecycline) as adjunct therapies in recurrent cases [48,49].  Teicoplanin has been 
shown to be noninferior to vancomycin, but is currently not approved for use in the 
United States [50].  Surotomycin and cadazolid are currently in Phase 3 clinical trials.  
There are also three human monoclonal antibodies with neutralizing activity against the 
toxins in Phase 3 clinical trials for use as a therapy to prevent recurrent CDI. 
 
Recurrence 
 An estimated 20-30% of CDI patients will have at least one recurrent infection.  
Approximately 25% of patients will have their first recurrence within the first 30 days 
after clearance and after the second recurrence, the rate of recurrence more than 
doubles [51].  The mechanism of recurrence is not well understood, but it is well 
documented that the recurring infection can be caused by the same strain or a 
completely different strain (45%) from the original C. difficile infection [35].  Predicting 
which patients are at greater risk of recurrence has been quite challenging.  Several 
studies have identified advanced age as the major risk factor.  Studies have also 
correlated previous use of fluoroquinolones, antibiotic and proton pump inhibitor use 
after initial clearance, and insufficient immune response to higher incidence of 
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recurrence [52].  The recommended treatment for recurrent infections is a vancomycin 
taper.  In high risk or multiple recurrent patients, a vancomycin pulse is frequently 
pursued along with adjunct therapies mentioned above.  The high incidence of 
recurrence remains a difficult problem contributing to high mortality rates (10% increase 
compared to primary infections) and highlights the need for more effective therapeutics 
[9,33]. 
 
 
Virulence Factors of C. difficile 
 
 Many factors are thought to contribute to the virulence of C. difficile.  Flagella 
[53,54], fimbrae [55], capsule [55], paracrystalline S-layer [56,57], adhesins [58], 
extracellular enzymes [59], cyclic diguanylate [60], and exotoxins [61-64] have all been 
implicated as virulence factors.  Most, however, are poorly understood and their 
functions in disease pathogenesis are highly speculative.  The functions of the 
exotoxins in disease are well accepted and the focus of many research efforts.  C. 
difficile secretes three large toxins: a binary toxin (CDTab) [61,62], and the main 
virulence factors, toxin A (TcdA), and toxin B (TcdB) [65].  While CDTab has been 
shown to contribute to virulence, it is not present in all pathogenic isolates [66].  TcdA 
and TcdB have been clearly implicated as virulence factors, as purified toxins can 
replicate pathogenic hallmarks in animal models [67-69].  Additionally, TcdA and TcdB 
can be detected in the stool of patients and animals exhibiting disease symptoms, and 
antibodies recognizing TcdA have been isolated from CDI patients [70-73].  Notably, 
TcdA-TcdB+ strains have been isolated but portions of TcdB have been mutated to more 
closely resemble TcdA [74,75].  No TcdA+TcdB- strains have been isolated thus far.  
Most recently, genetic knockouts of the toxins in the bacteria further implicate TcdA and 
TcdB as the main virulence factors and mediators of disease caused by C. difficile 
[63,64].  Understanding how C. difficile toxins cause disease has been delayed in part 
because of both the inability to manipulate C. difficile genetically and the absence of a 
recombinant expression system for the toxins.  Much of the early work on TcdA and 
TcdB was performed using native toxin, which is not easily or abundantly purified.  Both 
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of these problems are becoming less of an issue with the development and exploitation 
of genetic manipulation tools, like the ClosTron system [76,77], and the Bacillus 
megaterium expression system [78]. 
 
Pathogenicity locus  
 The genes encoding TcdA and TcdB are within the chromosome on what is 
known as the pathogenicity locus. The pathogenicity locus consists of 5 genes.  The 
genes  tcdA and tcdB encode the toxins;  tcdC and tcdD encode two regulatory 
proteins; and tcdE encodes a holin-like protein [79-81].  Little is known about TcdE, 
though it has been hypothesized that it may form pores in C. difficile through which the 
toxins are secreted [80].  TcdC is a negative regulator and TcdD a positive regulator of 
toxin expression [79].  C. difficile strains of the epidemic ribotype NAP1/027 have a 
deletion in the tcdC gene that is thought to result in increased toxin production [16].  In 
vitro, TcdA and TcdB are expressed in stationary phase and correlate with a decrease 
in TcdC and an increase in TcdD expression [81].  Temporal expression of toxins in vivo 
is not well understood. 
  
TcdA and TcdB are AB toxins 
TcdA and TcdB are broadly classified as AB toxins.  The A portion of the protein 
has enzymatic activity that is typically responsible for the function of the toxin and 
damage to host cells.  The B portion binds to the host cells and delivers the A portion of 
the toxin into the cytosol (Figure 1.1).  Many pathogenic bacteria secrete AB toxins 
including Bacillus anthracis, Corynebacterium diptheriae, and some of the Clostridia 
species.  A subclass of AB toxins, termed AB5 toxins, is similar in function secreting 5 
subunits of the B portion of the toxin, forming a pentamer.  Pathogens that secrete AB5 
toxins include Vibrio cholerae, Bordetella pertussis, and Shigella dysenteriae.   
 Large Clostridial Toxins (LCTs) are a subgroup of AB toxins secreted by some 
Clostridia.  In addition to TcdA and TcdB from C. difficile, this group includes 
hemorrhagic (TcsH) and lethal (TcsL) toxin from C. sordellii, α-toxin (Tcnα) from C. 
novyi, and large cytotoxin (TpeL) from C. perfringens.  The original domain assignments 
and much of the mechanism of toxin function was predicted for TcdA and TcdB based 
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upon homology to other LCTs and AB toxins.  TcdA and TcdB consist of four functional 
domains and were thought to intoxicate cells via identical mechanisms, both resulting in 
apoptosis of the host cell.  The enzymatic A portion of the toxins was identified as the N-
terminal region and shown to glucosylate Rho-family GTPases.  The C-terminal B 
portion of the toxins includes three domains with functions ascribed as autocleavage, 
pore-formation/delivery, and host cell receptor binding (Figure 1.1).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.  TcdA and TcdB primary structure and mechanism of cellular 
intoxication. A, TcdA and TcdB are homologous AB toxins consisting of four 
domains. The enzymatic A component is an N-terminal glucosyltransferase 
domain (GTD) (red). The B component, involved in delivery of the GTD into the 
cell, has three identified domains: combined repetitive oligopeptides (CROPs) 
(green), “delivery” or pore-forming (yellow), and autoprotease domains (blue). 
The orange box represents the hydrophobic region of the delivery domain that 
has been proposed to form part of the transmembrane pore (amino acids 956–
1128 of TcdB). B, The delivery process is divided into four main steps that are 
mediated by each of the four domains. (1) The toxin binds to the surface of the 
cell and is internalized by receptor-mediated endocytosis. (2) Acidification of the 
endosome triggers the formation of a pore through which the GTD is 
translocated. (3) The GTD is released into the cytosol by InsP6 dependent 
autoproteolysis. (4) The GTD glucosylates Rho family GTPases at the cell 
membrane [6]. 
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Host cell receptor binding 
   Host cell receptor binding was predicted to occur through the highly repetitive 
C-terminal portion of the toxin referred to as the CROPS (combined repetitive 
oligopeptides) domain, consisting of many 19-24 amino acid short repeats and 31 
amino acid long repeats.  TcdA CROPS contains 32 short repeats and 7 long repeats, 
while TcdB is significantly shorter with 19 short repeats and 4 long repeats [82,83].  This 
domain is defined as residues 1832-2710 and 1834-2366 in TcdA and TcdB, 
respectively [8].  Together, these repeats were shown to form cell wall binding motifs 
that could likely bind sugars [84,85].   TcdA CROPS was first shown to bind α-Gal-(1,3)-
β-Gal-(1,4)-β-GlcNAc, which is not expressed in the human colon [86,87].  TcdA was 
later shown to bind human I, X, and Y blood antigen as well as glycosphingolipid 
[87,88].  Notably, these sugars contain the β-Gal-(1,4)-β-GlcNAc identified previously, 
but the functional relevance of these sugars as ligands in the colon have not been 
demonstrated.  Structural studies have noted that the sugar binding pockets of TcdB 
have the opposite electrostatic charge of TcdA, providing structural evidence for the 
decreased affinity of TcdB for α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAc [8].    
 Two host cell proteins have been implicated in TcdA binding.  Sucrose-
isomaltase was identified as a potential receptor for TcdA in the ileum of rabbits [89].  
Binding was inhibited by galactosidase, suggesting that the interaction between 
sucrose-isomaltase and TcdA was mediated by an unidentified glycosyl modification.  
Unfortunately, sucrose isomaltase cannot be the receptor facilitating TcdA induced 
pathology in humans as it is not expressed in the human colon [89].  The heat shock 
protein gp96 has also been identified as a potential host cell receptor for TcdA [90].  
Consistent with previous data, gp96 is also predicted to be glycosylated, though the 
specific moieties remain unidentified.   
 Recently, chondroitin sulfate proteoglycan 4 (CSPG4) has been identified as a 
potential host cell receptor for TcdB [91].  Yuan et al. demonstrated that genetic 
knockout of the protein resulted in loss of CPE in tissue culture models.  They also 
demonstrated direct interactions between residues 1500 and 1851 of TcdB and CSPG4.  
In a CSPG4 genetic knockout mouse, however, mice continue to die when injected 
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intraperitoneally with purified TcdB.  These data suggest the potential for multiple 
receptors mediating toxin entry. 
 While the mechanism of host cell entry is not understood, both TcdA and TcdB 
are thought to enter cells via clathrin-mediated endocytosis [92].  Interestingly, it has 
also been shown that the CROPS domains of both toxins are not the only domains 
interacting with the surface of host cells.  Truncations lacking the CROPS in both TcdA 
and TcdB have been shown to enter and induce cytopathic and cytotoxic effects, albeit 
with reduced potency [93,94].  These data lend further evidence to multivalent binding 
capabilities of the toxins.  Identification of toxin receptors relevant to human disease and 
mechanism of toxin entry remain important areas of ongoing investigation. 
 
Delivery 
 After binding and internalization, the toxin must deliver its enzymatic A portion 
into the cytosol.  Based largely on analogy to other AB toxins, it is thought that TcdA 
and TcdB accomplish this translocation event with a pH sensitive conformational 
change in the endosome upon which the toxin forms a pore in the endosomal 
membrane.  This function was ascribed to the central, hydrophobic one-third of the 
toxins.   
 Though evidence for the formation of a pore has yet to be shown, other aspects 
of the proposed model of translocation have been supported.  TcdB was shown to 
undergo a conformational change in response to low pH using fluorescent probes and 
protease digests [95].  TcdB was also shown to form channels through which large ions, 
Rb+, could pass both on cells and artificial lipid bilayers in response to low pH [96,97].  
The hypothesis that this function is pathologically relevant was supported in tissue 
models with the pharmacological proton pump inhibitor, bafilomycin A1 [95,96].  
Bafilomycin specifically targets the V-ATPase responsible for the acidification of 
endosomes [98].  Pretreatment of cells with the inhibitor prevented the CPE caused by 
TcdB.  TcdA was also shown to form channels in cells and lipid bilayers.  In vitro bilayer 
experiments revealed a requirement for cholesterol in TcdA channel activity [97]. 
 Identification of the residues involved in pore formation has been difficult.  A 
cluster of particularly hydrophobic residues in the middle of the delivery domain (aa 958-
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1130 in TcdA and 956-1128 in TcdB) have been implicated as potential pore forming 
residues [82,85].  Genisyuerek et al. attempted to identify essential residues by 
investigating a series of TcdB truncations.  They found that a fragment consisting of 
residues 1-1500 contained the complete translocation machinery necessary for cell 
intoxication.  They noted that residues 830-1025 were sufficient to allow channel activity 
in lipid bilayers, though they were careful to acknowledge that channel activity and 
translocation machinery are not necessarily the same [99].  There are only two studies 
to date that identify specific residues involved in pore formation.  One study identified 
two residues, E970 and E976, as residues that when mutated prevented channel 
activity in lipid bilayers and CPE on tissue culture cells [99].  The most recent study by 
Zhang et al. identified four residues with a 99% reduction in toxicity and no detectable 
channel activity.  Based on striking homology to diphtheria toxin, they proposed a 
similar model in which TcdB inserts a double-hairpin into the endosomal membrane.  
The authors acknowledge that the model does not address the outstanding question of 
whether or not TcdA and TcdB form oligomeric pore structures [100]. These data 
present an exciting new avenue for investigation of the mechanism of pore-formation 
and translocation and how it relates to intoxication.   
 
Autocleavage 
 LCTs are synthesized and secreted as single polypeptide chains.  As in other AB 
toxins, however, the enzymatic A subunit was thought to be released into the host cell 
cytosol.  It was, therefore, assumed that the LCTs undergo a cleavage event that 
releases the A subunit after translocation into the cytosol.  The N-terminal A subunit of 
TcdB was shown to be released into the host cell in 2003 [101].  A couple of years later, 
the cleavage site was identified as the amide bond between residues Leu543 and 
Gly544 [102].  This proteolytic event was also shown to be dependent upon a host cell 
factor, presumably a protease.  Reineke et al. instead identified host cell inositol 
phosphates as the essential activator mediating the apparent autoproteolysis.  Inositol 
hexakisphosphate (InsP6) was shown to be the most efficient activator, though InsP3 
and InsP4 were also effective.  In the absence of host cell lysate, purified InsP6 was 
sufficient to induce TcdB autoprocessing [103].   
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 The autoproteolysis of TcdB was first attributed to aspartyl protease activity using 
epoxy-3(p-nitophenoxy)propane (EPNP) which specifically modifies protease active 
aspartates.  EPNP was shown to inhibit autoprocessing in TcdB and Asp1665 was 
identified as the covalently modified residue [103].  This report was quickly contradicted 
and the autocatalytic activity of TcdA and TcdB was demonstrated to be dependent 
upon cysteine protease activity [104].  Based on homology to the Vibrio cholerae 
MARTx (VcRTx) toxin, an AB toxin also shown to have cysteine protease 
autoprocessing activity, the autoprocessing domain (APD) was identified and localized 
to the region directly C-terminal to the enzymatic A subunit released into the host cell.  
These observations were confirmed with site-directed mutagenesis of the proposed 
catalytic site residues (Cys698, His653 and Asp587 in TcdB) and cysteine protease 
inhibitors that covalently modify the catalytic cysteine [104].   
 Since this report, many studies have been conducted to define the function of 
this domain and its activity in the context of cellular intoxication.  If the enzymatic A 
domain must be released into the cytosol to target its host cell proteins, one would 
predict that the autocleavage activity of the APD would be essential for toxin function 
within the cell.  To try to test this hypothesis, APD point mutants were tested using a 
number of cell based readouts, most often looking for CPE [3,32,103-105].  In these 
assays, autoprocessing was found to be essential for the CPE mediated by TcdA and 
TcdB. 
 
Glucosyltransfer 
 The N-terminal 63 kDa enzymatic A subunit released upon InsP6-dependent 
autocleavage is a glucosyltransferase capable of modifying Rho family GTPases [106-
110].  The GTPase targets of LCTs are known to regulate essential cellular processes 
including cell cycle progression, cellular adhesion, cytokinesis, secretion, and 
cytoskeletal maintenance [111].  The glucosyltransferase domain (GTD) of TcdA and 
TcdB hydrolyzes a UDP-glucose molecule and transfers the glucose to a threonine in 
the switch one region of the small GTPases [106].  The GTDs of TcsH and TcsL also 
use UDP-glucose as a substrate [110].  Tcnα uses UDP-GlcNAc, and TpeL can use 
either UDP-glucose or UDP-GlcNAc [112,113].  The toxins preferentially modify the 
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GDP bound state of GTPases, locking the enzyme in the inactive conformation and 
preventing its association with downstream effectors [106,109].  This inactivation leads 
to profound cytoskeletal rearrangements resulting in cell rounding (CPE).  The 
inactivation has also been thought to cause loosening of tight junctions, prevention of 
cell proliferation, and ultimately an apoptotic cell death [20,114-120].   
 It is thought that the GTD is likely targeted to the plasma membrane, where its 
substrates are most often found.  The membrane localization domain (MLD) was 
determined to be included within the first 70 residues of TcdA and TcdB, again based 
largely on homology to VcRTx [121].  In vitro experiments have demonstrated that the 
C. difficile toxins can modify RhoA, RhoB, RhoC, RhoG, Rac1, Cdc42, and TC10 
[83,122].  TcdA can additionally glucosylate the Ras-like proteins Rap1A and Rap2A 
[123].  TcsH and Tcnα also modify Rho family proteins [112,124] while TcsL and TpeL 
preferentially modify the Ras family proteins H-Ras, Ral, and Rap [113].  Interestingly, 
they can glucosylate Rac but not Rho proteins.  Clinically isolated TcdA-TcdB+ strains 
have been shown to be conserved in every domain of the prototypical TcdB except the 
GTD.  There are a number of residue differences that are thought to contribute to the 
GTPase substrate shift to those of TcsL instead of TcdB [125-127].  The mechanism of 
substrate recognition is not well understood, but it has been well documented that 
modification of different substrates leads to different cellular effects.   
 The glucosyltransferase (GT) activity of TcdA and TcdB is thought to be essential 
to toxin function, eventually leading to host cell apoptosis.  This has been demonstrated 
by a number of groups in a number of cell lines most often using CPE as the readout for 
toxin function.  There are many reports showing mutagenesis of essential residues that 
result in defective GT activity in vitro result in loss of CPE.  These studies and the 
implications of their findings on the function of the GTD in tissue culture models are 
discussed in more detail in the next section. 
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Pathological Functions of TcdA and TcdB 
 
Animal models 
 TcdA and TcdB have been studied in several animal models including mice, rats, 
hamsters, and rabbits.  They have been shown to have different effects depending on 
the model system and method of intoxication.  In most models, TcdA has a more 
profound effect, inducing fluid accumulation and inflammation, whereas TcdB has little 
effect [67,68].  The rabbit ileal loop, for example, has been used extensively as a model 
system for understanding the relative functions for the toxins in tissue damage and fluid 
secretion.  In this model, TcdA induces fluid accumulation, inflammation, and extensive 
tissue damage, whereas TcdB has no effect [68].  Notably, when the toxins are injected 
intraperitoneally, TcdA and TcdB kill the animals with similar potencies [128].  Also, 
TcdB has been reported to be 100-10,000 times more potent than TcdA in tissue culture 
models [123,129-131].  These observations led to the distinctions of TcdA as an 
enterotoxin and TcdB as a potent cytotoxin because of its potency in tissue culture 
models.  The lack of potency exhibited by TcdB in animal models resulted in a 
hypothesis that TcdA acted as the main virulence factor, disrupting the colonic 
epithelium and causing disease symptoms while providing TcdB with access to other 
tissues [65].  Lyerly et al. provided supporting evidence of this idea with experiments 
showing that hamsters died when intoxicated with TcdB in conjunction with sublethal 
doses of TcdA or if first subjected to intestinal damage.  In this pathogenic model, TcdB 
was acting as an accessory virulence factor, which is inconsistent with the isolation of 
TcdA-TcdB+ clinical strains [75].  Also inconsistent with this model are data describing 
the effects of TcdA and TcdB in human colonic explants and xenografts.  TcdB was 
found to be at least 10 times more potent against colonic explants, and both toxins 
induced necrosis and inflammation in the xenograft model [132,133].   
 In 2009, two studies reported the first genetic manipulations of C. difficile.  Both 
reports demonstrated the construction of tcdA and tcdB knockouts in otherwise isogenic 
630erm strains.  Lyras et al. showed that the TcdA-TcdB+ strain killed hamsters with the 
same potency as the TcdA+TcdB+ strain.  The TcdA+TcdB- strain, however, showed a 
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significant loss in virulence, implicating TcdB as the major virulence factor [63].  Kuehne 
et al. reported soon after that both TcdA and TcdB were essential for virulence, 
demonstrating a loss in virulence for both TcdA-TcdB+ and TcdA+TcdB- strains [64].  
There have been two further reports involving studies with knockout strains, however,  
the interpretation of these data remain somewhat unclear [134,135].  The requirement 
for one toxin over the other in disease pathology is a point of contention within the field.   
 In addition to gross pathological effects, cytokine release has also been 
investigated in response to TcdA and TcdB in both animal and tissue culture models.  
TcdA has been shown to result in the production of IL-1, IL-6, IL-8, tumor necrosis 
factor, intestinal secretory factor, transforming growth factor β, substance P, and 
macrophage inflammatory protein 2 [119,136-140].  The cytokine profile has not been 
as extensively characterized in response to TcdB, though IL-1, IL-6, and IL-8 secretion 
have been reported [133].  Importantly, IL-8 is known to recruit and activate neutrophils 
at sites of infection [141]; neutrophil infiltration is a hallmark of CDI. 
  
Tissue culture models 
 TcdA and TcdB were thought to intoxicate and induce cell death by identical 
mechanisms (Figure 1.1).  They are often used interchangeably and rarely compared 
directly in the same study using tissue culture models.  Both toxins have been reported 
to have a number of effects on a number of different tissue culture cell lines.  The most 
obvious and commonly used readout for intoxication with TcdA and TcdB is CPE.  The 
toxins are also known to kill cells.  Unfortunately, the terms cytopathicity and cytotoxicity 
have been used interchangeably to describe cell rounding without the use of true 
viability readouts.  Many studies have described the cell death induced by both TcdA 
and TcdB as apoptotic, though the pathway leading to apoptosis has been unclear 
[9,20,21,142-149].  The apoptotic pathways of both TcdA and TcdB have been 
described as both p53-dependent and p53-independent as well as both caspase-
dependent and caspase-independent [115,150-152].  One study reported an absence of 
apoptotic markers when cells were intoxicated with higher concentrations of TcdB, 
suggesting a necrotic cell death [21]. 
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 The development of a recombinant expression system made it possible to begin 
dissecting the contributions of different domains and enzymatic activities to toxin 
function.  Most extensively studied were the enzymatic activities of the GTD and APD.  
In several studies, essential residues were mutated rendering the toxins deficient in 
their glucosyltransferase functions and assessed the impact of these mutations in cells.  
The majority of reports concluded that the GT activity of both toxins was required to 
achieve apoptosis.  Assay readouts included CPE, caspase activation, cell proliferation, 
and DNA fragmentation. Similarly, the contribution of the APD enzymatic activity was 
determined to be essential for the induction of apoptosis after intoxication with both 
TcdA and TcdB.  The readouts used in these reports included CPE, caspase activation, 
and Rac1 modification.  A publication by Kreimeyer et al. determined that the 
autoprocessing activity of TcdA was not essential to cytotoxicity but was a determinant 
of potency [105].   
 The variation among studies including the cell types, assays, toxins, toxin 
concentrations, observations, and terminology have resulted in confusion and 
seemingly conflicting ideas about the mechanism of cellular intoxication.  These 
complications have made it difficult to extrapolate data acquired in these model systems 
to relevance in disease pathology.  It highlights the need for rapid and convenient model 
systems that accurately and consistently recapitulate the observations made in human 
disease.   
 
Structural Insights into TcdA and TcdB 
 
 One goal of the Lacy laboratory is to determine the structures of the toxins.  Our 
lab has been successful in determining the crystal structures of individual domains of 
TcdA as well as a low resolution electron microscopy derived 3-dimensional 
reconstruction of the holotoxin.  The structural insights gained from these and other 
studies are described in more detail. 
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Electron Microcopy of TcdA holotoxin 
 Our lab captured images of the TcdA and TcdB holotoxins using negative stain 
electron microscopy (EM) (Figure 1.2) [5].  In collaboration with Dr. Melanie Ohi, Dr. 
Rory Pruitt used random conical tilt to reconstruct a 3-dimensional structure of the toxin 
at ~20 Å resolution.  The TcdA structure consists of a globular head domain with two 
tails, one long tail and one short tail, protruding from the base of the head. The 2-
dimensional negative stain images of TcdB look very similar to TcdA, differing in the 
length of the long tail (Figure 1.1) [5].  
 
 
 
 
The Ng laboratory published a model of the TcdA CROPS domain based on their 
determination of the crystal structure of a small fragment from this repetitive domain [8].  
They predicted the entire domain would adopt an elongated serpentine-like structure 
(Figure 1.3A) [8].  This prediction and electron micrographs of the CROPS domain 
Figure 1.2.  Electron 
microscopy reveals the 
first images of TcdA 
holotoxin.  Typical electron 
micrographs of A, TcdA and 
B, TcdB.  Class averages are 
shown in the top right corner 
of each panel.  C, A 3-
dimensional reconstruction of 
TcdA using random conical 
tilt reveals a globular head 
domain, a short tail and a 
long tail [5]. 
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alone (878 aa) allowed the identification of the CROPS domain as the long tail in the 
holotoxin structure (Figure 1.3) [5].  The localization of the CROPS domain to the long 
tail is consistent with the observation that the long tail is significantly shorter (532 aa) in 
the TcdB structure.  The CROPS domain appears to interact with at least two other 
parts of the protein.  There is contact between the base of the head domain and the N-
terminal portion of the CROPS and there may also be contact at the tip of the short tail 
and the middle of the CROPS domain (Figure 1.3) [5].  Determining the location of the 
GTD, APD, and delivery domain will be important in understanding the function of the 
interactions observed with the CROPS domain.   
 
 
 
 
 
 
The EM structure of TcdA also provided insight into the conformational change 
that is thought to occur upon encountering the low pH of the endosome.  A second 
structure was generated from TcdA particles exposed to acidic pH (Figure 1.4) [5].  
There is a significant rearrangement of the positions of the short tail and globular head.  
At pH 4.5, the short tail is no longer positioned somewhat parallel the CROPS, but is 
rotated out creating a more elongated structure (Figure 1.4) [5].  Determining a high 
resolution structure of the holotoxins and identifying the location of the domains remains 
a high priority for further study.   
Figure 1.3.  Localization of the CROPS with the TcdA 
holotoxin structure.  A, Proposed model of TcdA CROPS 
domain [8].  B, EM average of negative stained TcdA.  C, 
Negative stained particle of TcdA CROPS.  D, Typical electron 
micrograph of TcdA CROPS [5]. 
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Crystal structures of the glucosyltransferase domains 
 The crystal structure of the TcdB GTD was determined in 2005 by Reinert et al.  
The GTD was crystallized in the presence of the UDP-glucose substrate, which was 
found to be hydrolyzed within the active site of the protein [153].  In addition to 
mechanistic insight, the structure revealed a core Rossman fold that is common among 
glycosyltransferase A (GT-A) family members.  The GTD consists of four α-helical 
bundles in addition to the core GT-A fold [153].  The most N-terminal bundle is thought 
to be involved in membrane localization [121,154].  The function of the other α-helical 
sub-domains is hypothesized to include GTPase substrate binding, though data 
supporting this hypothesis are minimal [10].  The structure revealed residues involved in 
binding UDP-glucose and the metal cofactor, Mn2+, which when mutated demonstrated 
significant enzymatic deficiencies [10,153].  Among these essential residues are those 
involved in binding UDP-glucose (Tyr284, Asp286, Asp270, Asn394, S518 and Trp520) 
and Mn2+ binding, Asp288.  Trp520 forms a hydrogen bond with the glycosidic oxygen 
Figure 1.4.  Structural evidence of a pH-induced 
conformational change of TcdA.  3-dimensional reconstruction 
of TcdA at A, pH 7.0 and B, pH 4.5.  Both structures were 
achieved using random conical tilt.  The CROPS domain is 
colored green [5]. 
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of UDP-glucose and is thought to be involved in hydrolysis and transfer of the glucose 
to the GTPase target (Figure 1.5B) [10].  
The structure of the TcdA GTD was determined in both the apo and UDP-
glucose bound states (Figure 1.5A) [2].  The major difference between the apo and 
substrate bound structures was the position of Trp519 (Trp520 in TcdB).  The residue 
hydrogen bonds with the glycosidic oxygen in the UDP-glucose bound structure but is 
10 Å away from the active site in the apo structure (Figure 1.5C) [2].  A similar loop 
movement has been described in mammalian glycosyltransferases as a “lid” covering 
the substrate upon binding [155].  This loop movement may be a function of mechanistic 
efficiency for the enzyme.   
  
 
 
 
 
 
 
 
 
 
 
Figure 1.5.  Structures of TcdA and TcdB GTD.  A, The putative membrane localization 
domain (MLD) is highlighted toward the N-terminus of the TcdA GTD.  The active site is 
highlighted in the box [2].  B, The active site of TcdB identifying residues that bind the UDP-
glucose substrate.  The active site is shown in 3-dimensions (upper panel) with the substrate in 
blue sticks and in 2-dimensions (lower panel) for clarity [10].  C, An illustration of the Trp519 
movement observed upon UDP-glucose binding.  Shown in pink is the apo position.  The 
substrate-bound position is colored yellow [2]. 
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The TcdA holotoxin glucosyltransferase activity has been described as 100 times 
less efficient than that of the TcdB holotoxin [123] and was thought to contribute to the 
even greater discrepancy in potency described between the toxins in tissue culture 
models [123,129-131].  When comparing the structures of the GTD active sites, 
however, the only noticeable difference was that the UDP-glucose is hydrolyzed in the 
TcdB GTD structure and intact in the TcdA structure [2].  Otherwise, the structures are 
nearly identical, providing no obvious structural or mechanistic basis for the difference in 
potency.  Pruitt et al. went on to show that the activities of the isolated domains are very 
similar to each other and enhanced compared to their activities in the context of the 
holotoxin [2].  These observations are reasonable with respect to the proposed 
mechanism in which the GTD is translocated from the endosome, autoproteolyzed, and 
trafficked to the membrane where it can modify its target GTPases in the host cell. 
 
 
 
 Though there was little difference in the overall structure of the GTDs, there was 
a striking difference between TcdA and TcdB in the electrostatic potentials on the 
surface of the putative GTPase binding sites [2].  TcdA has a highly positively charged 
pocket, whereas TcdB has a highly negatively charged group of surface residues 
Figure 1.6.  Surface electrostatic 
charges of TcdA and TcdB are 
different.  Though the overall 
structures are highly similar, A, TcdA 
and B, TcdB differ in their surface-
exposed charged residues.  Positively 
charged residues are colored blue.  
Negatively charged residues are 
colored red [2]. 
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(Figure 1.6).  Pruitt et al. hypothesized that this difference could be the structural basis 
of the reported difference in substrate specificity between TcdA and TcdB [2].  Efforts to 
control substrate specificity through the targeted mutagenesis of these surfaces, 
however, have been unsuccessful. 
 
Crystal structures of the autoprocessing domains 
 The structures of the autoprocessing domains of both toxins have also been 
determined [3,4].  Prior to the determination of the structures, the domain was described 
as a cysteine protease using both site-directed mutagenesis of active site residues 
(C700, H655, and D589 in TcdA) and pharmacological inhibitors [104].  Additionally, it 
was also known that the activity of the protease was dependent upon a host cell factor, 
inositol hexakisphosphate (InsP6) [4,103,156].  Upon the elucidation of the structure of 
the TcdA APD, two important observations were made (Figure 1.7).  First, InsP6 was 
bound in a basic pocket containing six lysine and two arginine residues, similar to the 
VcRTx APD structure [4,157].  InsP6 was bound on the protein face opposite the active 
site, suggesting an allosteric mechanism of activation.  Allostery was proposed to be 
communicated through what was termed the β-flap (Figure 1.7A) [4].  This mechanism 
of activation was confirmed and investigated in more detail in later studies [158].  The 
second important observation was that the active site residues were not in a 
conformation typical of a cysteine protease triad (Figure 1.7B) [4].  In a typical cysteine 
protease, the nucleophilic cysteine is activated by a residue that is hydrogen bonded, 
typically a histidine [159,160].  The structure revealed an active site conformation in 
which the Cys700 was ˃ 6 Å from His655 and ˃ 10 Å from Asp589 [4].  Though this 
conformation had been observed in the structure of VcRTx [157], it suggested an 
atypical mechanism of proteolysis.   
 Puri et al. determined the structure of the TcdB APD in the presence of covalent 
inhibitors and the allosteric activator, InsP6.  The dipeptide inhibitors were substrate 
mimics covalently bound to the catalytic cysteine, thus providing insight into the 
conformation of the substrate bound protease [3].  The similarity to the structure of the 
substrate bound VcRTx protease domain was quite striking [1].  Again, both structures 
revealed an atypical active site conformation in which the substrate lies between the 
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catalytic cysteine and the histidine [1,3].  These observations further suggested a 
unique mechanism of proteolysis. 
 
 
 
  
 
 
 
 
 
Comparison of the TcdA and TcdB APD structures again revealed no obvious 
structural or mechanistic reason for differences in toxin potency as they were nearly 
identical.  Notably, it has been reported that TcdA requires high concentrations of 
reducing agent, such as dithiolthreitol (DTT), in addition to InsP6 before autoprocessing 
could occur [104].  TcdB, however, can initiate autoprocessing with the addition of InsP6 
only [102,103].  The resulting assumption was that a disulfide bond [104], present in 
TcdA and not in TcdB, must be reduced before cleavage could occur.  While this 
difference in autoprocessing efficiency could potentially explain the differences in 
potency in cells between the two toxins, no investigations were made to formally test 
either of these hypotheses.   
 
 
Figure 1.7.  The structure of the TcdA APD reveals and 
allosteric InsP6 binding site and an unusual active site 
conformation.  A.  The TcdA APD (residues 543 to 809).  
The active site residues are colored orange; InsP6 is 
colored red; and the β-flap is colored purple.  B, The TcdA 
APD active site is in an unusual conformation for cysteine 
protease activity [4]. 
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Research Objectives 
 
 
 At the outset of this project, one of my goals was to conduct a high throughput 
small molecule inhibitor screen for compounds that protected cells from TcdB-induced 
cell death.  As a primary mediator of CDI, we wanted to target TcdB for the 
development of new, more effective therapeutics.  We conducted a cell-based, high 
throughput small molecule inhibitor screen to identify compounds that provided 
protection from TcdB-mediated cell death.  We expected to find compounds that 
inhibited the enzymatic activities of TcdB as they were thought to be essential for TcdB 
induced apoptosis.  The GTD and APD both presented attractive binding sites for 
inhibitors in their active and allosteric sites.  We also recognized that compounds could 
be inhibiting any step of the cell death pathway, including binding the host cell receptor, 
pore formation, or downstream effects of GTPase modification.  Through the course of 
conducting the screen and developing controls for inhibitors we predicted we would find 
against the GTD and APD activities, we made some surprising discoveries. 
 In Chapter II, I present data demonstrating TcdB induces necrosis.  We 
employed a number of necrotic markers, including rapid ATP depletion, lactose 
dehydrogenase (LDH) release, and high-mobility group protein B1 (HMGB1) 
relocalization as well as the absence of apoptotic markers such as active caspase-3 to 
support our claims.  Activated caspases were nearly undetectable in response to TcdB 
in our tissue culture models.  TcdA induced low levels of caspase activation at high 
concentrations 48 hours post-intoxication in our cell lines.   Using site-directed 
mutagenesis, we went on to show that the autoprocessing and glucosyltrasferase 
activities of TcdB are not required to induce the necrotic cell death we were observing at 
nanomolar concentrations of toxin.  Because the necrotic phenotype was occurring at 
higher concentrations than what is typically used in CPE assays, we also provided 
evidence that nanomolar concentrations of toxin are pathologically relevant using a 
colonic explant model.  This work provided a mechanism of cell death that could explain 
the underlying pathology of the necrotic lesions, typical of CDI.  This work also 
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highlighted the unlikelihood that the autoprocessing activity of TcdB would be a viable 
drug target. 
 In collaboration with Dr. Melissa Farrow, we went on to define the mechanism of 
necrosis induced by TcdB as being dependent upon the assembly and activation of the 
NADPH oxidase (NOX) complex and subsequent reactive oxygen species (ROS) 
production.  With this new understanding of how cells were dying, we were able to 
return to the small molecule inhibitor screen with new, relevant, and testable targets for 
inhibition in mind.  We have chosen to focus on one compound, 0049, as a 
representative of the major class of compounds that came out of the screen as 
confirmed hits.  Our progress on this ongoing work is presented in Appendix I.   
 In the experiments performed in Chapter II, we made the perplexing observation 
that TcdA-induced cell death was detectable only at high nanomolar concentrations of 
toxin 48 hours post-intoxication.  Reports of TcdA activity on tissue and in animal 
models had indicated that TcdA was a more potent toxin than what we were observing 
in our tissue culture models.  We sought to understand why our observations in cells 
were not an accurate reflection of pathological activity of TcdA.  Young adult mouse 
colonic (YAMC) epithelial cells express a temperature dependent simian virus 40 
(SV40) T-antigen that disrupts p53.  These cells provide a unique tool in that they are 
an easily carried cell line at the permissive temperature where p53 is disrupted and are 
a relevant primary cell line at the non-permissive temperature where the cells can 
undergo normal apoptosis.  We exploited this cell line to investigate the effects of TcdA 
and TcdB intoxication side by side in the same cell line using the same assay readouts.  
In Chapter III, we clearly demonstrate that TcdA is a potent cytotoxin, inducing cell 
death to levels similar to TcdB.  Cell death induced by TcdA is apoptotic and dependent 
upon the p53 pathway and glucosyltransferase activity.  We were also able to show that 
TcdB induces a concentration dependent bimodal profile of cell death.  At higher 
concentrations, TcdB induces glucosyltransferase independent necrosis, as previously 
described, and at lower concentrations, TcdB induces a p53, glucosyltransferase 
dependent apoptotic cell death.  These observations were recapitulated in our colonic 
explant model.  This work highlights the need to work in model systems capable of 
undergoing normal apoptosis when studying the cell death pathway induced by TcdA 
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and the concentration-dependence of TcdB phenotypes.  The data presented in 
Chapter III provide the opportunity to coalesce the field’s observations that have 
appeared to be conflicting in recent years. 
 Another goal of my project was to understand the difference in TcdA and TcdB 
autoprocessing activity.  As presented in Chapter IV, we discovered that TcdA 
autoprocessing is regulated by the coordination of zinc ions.  TcdA coordinates at least 
3 zinc ions, two for which we have defined functions.  One zinc ion acts as a regulator of 
autoprocessing; its presence inhibits autoprocessing and its removal allows 
autoprocessing to occur normally.  Interestingly, this zinc ion is not present in TcdB, and 
once removed from TcdA, by chelators or low pH in vitro, autoprocessing can occur as 
efficiently as in TcdB.  The second zinc was unexpectedly localized to the active site of 
the APD.  We demonstrated that autoprocessing is dependent upon the presence of this 
zinc ion, suggesting the enzymatic mechanism of autoprocessing of both toxins is that 
of a zinc protease, not a cysteine protease as previously described.  The data 
presented here represent two novel zinc dependent mechanisms for the functions of C. 
difficile toxins. 
 Together, these data have advanced our understanding of the mechanisms by 
which TcdA and TcdB intoxicate and kill cells.  The insights presented here can help 
direct drug discovery efforts and development of more effective therapeutics to combat 
CDI.  Our ongoing work to understand the mechanistic aspects of cell death induced by 
C. difficile toxins and our ideas for future experiments are discussed in Chapter V. 
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CHAPTER II 
 
 
CLOSTRIDIUM DIFFICILE TOXIN B CAUSES EPITHELIAL CELL NECROSIS 
THROUGH AN AUTOPROCESSING-INDEPENDENT MECHANISM 
 
 
Introduction 
 
 Clostridium difficile is a gram-positive, spore-forming anaerobe that infects the colon 
and causes a range of gastrointestinal disorders including diarrhea, 
pseudomembranous colitis, and toxic megacolon [65,161].  This is a major healthcare 
concern as the number and severity of C. difficile-associated disease (CDI) cases have 
increased dramatically in recent years [162].  Two large toxins, TcdA and TcdB (308 
kDa and 270 kDa, respectively), are recognized as the main virulence factors of C. 
difficile [63,64].  The C-terminal portion of these toxins is responsible for delivering an 
N-terminal glucosyltransferase domain (GTD) into the host cell [102,163]. The GTD 
inactivates Rho family GTPases including Rho, Rac1, and Cdc42 [109,110].  
 While there are numerous studies that report the effects of toxin-mediated 
glucosylation in cells, a consensus as to the conclusion of these reports, taken together, 
has been difficult due to differences in cell types, toxin concentrations, and assay 
methods.  In addition, it appears that TcdA and TcdB can elicit different effects under 
similar conditions [68,164].  In all reports, both toxins can induce a cytopathic effect 
characterized by cell rounding.  In many reports, these cells go on to die by apoptotic 
mechanisms, but the time course can be up to 48 hours [9,20,115,143-145,150,151]. It 
has been noted, however, that apoptosis cannot be detected in cells treated with higher 
concentrations of TcdB [142].  In at least one study, the absence of apoptosis in cells 
treated with TcdB has led to suggestions of a necrotic mechanism of cell death [21]. 
 The mechanism of GTD delivery for TcdA and TcdB involves binding a host cell 
receptor [82,165], uptake by endocytosis [92,166], pH-dependent pore formation [95-
97], translocation across the endosomal membrane, host-factor dependent 
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autoprocessing [103], and release of the GTD into the host cell cytosol [101].  Release 
is thought to allow the GTD access to the Rho-family GTPases tethered to the plasma 
membrane surface.  An N-terminal sub-domain within the GTD is thought to serve as a 
membrane localization domain [121]. 
 The autoprocessing function of the toxins is mediated by a cysteine protease domain 
(CPD) that follows the N-terminal GTD [104]. Inositolphosphates, predominantly inositol 
hexakisphosphate (InsP6), have been identified as the host factors responsible for 
inducing autoprocessing [103].  The InsP6-bound structures of the TcdA and TcdB 
CPDs reveal a positively charged InsP6-binding pocket that is distinct from the catalytic 
active site [3,4]. InsP6 binding is thought to trigger conformational changes that permit 
the formation of the substrate-binding pocket and alignment of the catalytic residues 
[158].  The three catalytic amino acids Asp587, His653, and Cys698 (TcdB sequence) 
and the P1 substrate recognition site, Leu543, have been shown to be important for in 
vitro processing activity by genetic mutation [104]. Mutation and chemical modification 
of these residues has also been shown to prevent activity in various cell based assays 
[3,32,35,103,104].  For this reason, TcdB autoprocessing activity and GTD release have 
been considered important in the toxin mechanism, an idea which suggests that the 
CPD could serve as a useful target for novel small molecule inhibitor discovery.  
 The objective at the outset of this project was to conduct a high-throughput screen 
for small molecules that inhibit TcdB-mediated cell death. Our first step toward exploring 
this potential was to evaluate apoptotic and necrotic markers as cell death indicators.   
In observing a necrotic response to TcdB, we decided to specifically focus on the 
question of whether the assay would be able to detect inhibition of TcdB 
autoprocessing. We constructed mutant TcdB proteins with deficiencies in either the 
autoprocessing or glucosyltransferase activities and tested their effects on cell viability.  
Our unexpected observation that the mutants killed cells rapidly and at concentrations 
comparable to wild-type led us to investigate the role of autoprocessing and GTD 
release in cell death and cell rounding in greater detail.  In this report, we provide 
evidence that epithelial cells and porcine colonic tissue challenged with TcdB undergo a 
rapid, necrotic cell death that is not dependent on autoprocessing and GTD release.   
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Methods 
 
Ethics statement  
This study was performed in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health.  Animal husbandry and experimental procedures related to the porcine colonic 
explants were performed in accordance with the Vanderbilt University Institutional 
Animal Care and Use Committee (IACUC) policy.  Discarded colon tissues were 
obtained from pigs following euthanization at the end of IACUC-approved animal use 
protocols.  Animal husbandry and experimental procedures related to the generation of 
the anti-TcdBGTD monoclonal antibody were performed in accordance with the 
Washington University Animal Studies Committee policy, approval number 20100113.  
 
Expression of recombinant proteins  
Single amino acid point mutations were made in the TcdB autoprocessing active 
site (C698S, C698A, H653A, and D587N), the cleavage site (L543A), and the 
glucosyltransferase domain (D270N, D270A, Y284A, N384A, and W520A) using the 
QuickChange mutagenesis protocol (Stratagene).  The template for mutagenesis and 
clone for the production of wild-type TcdB was a B. megaterium expression vector 
encoding the strain 10643 of TcdB [5]. A similar clone was used for expression of 
recombinant TcdA [5]. Plasmids for expressing TcdA, TcdB, and TcdB point mutants 
were transformed into B. megaterium according to the manufacturer’s instructions 
(MoBiTec, Göttingen, Germany).  1 L of LB was inoculated with 35 mL overnight culture 
and 10 mg/L tetracycline and grown at 37 °C and 230 rpm.  At an OD600 of 0.3, 
expression was induced with 5 g of D-xylose.  Cells were harvested after 4 h by 
centrifugation and resuspended in 20 mM Tris, pH 8.0, 500 mM NaCl and protease 
inhibitors.  Cells were lysed by French press, and lysates were centrifuged at 48,000 g 
for 25 min.  The proteins were purified by Ni-affinity chromatography, Q-sepharose 
anion exchange chromatography, and gel filtration chromatography in 20 mM HEPES, 
pH 6.9, 50 mM NaCl. 
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Protein purification from C. difficile   
Proteins were expressed and purified as previously described [65]. 
 
Cell death assays   
HeLa and Caco2 cells (cultured in DMEM, 10% FBS, 5% CO2 and MEM, 10% 
FBS, 5% CO2, respectively) were seeded in a black 384-well plate at a concentration of 
3,000 or 1,000 cells/well, respectively.  HeLa cells were intoxicated the next day, and 
Caco2 cells were intoxicated 36 h later.  After intoxication, the cells were incubated at 
37 °C, 5% CO2 for either 2.5 h (HeLa) or 18 h (Caco2).  The amount of ATP (cell 
viability) was assessed with a luminescence-based indicator, CellTiterGlo (Promega).  
LDH release was assessed with a luminescence-based indicator, CytoToxGlo 
(Promega).  Caspase-3/7 activation was determined using a fluorescent indicator, Apo-
One (Promega).  Staurosporine (Sigma, 1mM) was used as a positive control for 
caspase-3/7 activation.  Plates were read in a Biotek Synergy 4 plate reader. 
 
HMGB1 release   
HeLa cells were seeded into a tissue culture treated chamber slide at 2 x104 cells 
per well and incubated overnight.  Cells were synchronized at 4 °C and intoxicated with 
10 nM TcdB for 1 h.  Cells were then shifted to 37 °C for 1 h.  Media was removed from 
the cells, and the cells were washed with PBS.  They were fixed with 4% 
paraformaldehyde at room temperature for 10 minutes and quenched with 1 mM 
glycine.  Cells were permeated with 0.2% Triton X-100 in PBS for 5 minutes, washed in 
PBS, and blocked for 30 minutes in PBS, 2% BSA, 0.1% Tween 20.  Cells were stained 
with a monoclonal antibody against HMGBI (Abcam, ab77302), and an Alexa Fluor 488 
anti-mouse antibody (Invitrogen, A11001).  Cells were visualized with an LSM 510 
Confocal microscope. 
 
In vitro cleavage assay   
1 uL InsP6 stock solution (100X) or buffer was added to 200 nM TcdB or TcdB 
autoprocessing mutant and incubated for 2 h at 37 °C.  The reactions were stopped with 
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the addition of loading buffer and boiling and analyzed by Coomassie stained SDS 
PAGE.  
 
Anti-TcdBGTD antibody generation  
Genomic DNA of C. difficile clinical isolate 630 was obtained from American Type 
Culture Collection, and the region encoding residues 1 to 549 of TcdB, which is known 
to encode the substrate binding and enzymatic domains of the toxin, was amplified in 
frame with a carboxy-terminal (His)6-tag using upstream primer :5’- 
CCGGATGTACAGTTGAGGGGGTAAAATGAGTTTAGTTAATAGAAAACAGTTAG -3’ 
and downstream primer 5’- 
GGTCCTCAATGATGGTGATGGTGATGAAGATTATCATCTTCACCAAGAGAACC -3’. 
The resulting product was cloned into plasmid pcDNA3.1 (Invitrogen, Carlsbad CA) and 
sequenced to ensure fidelity of the amplified product. The gene was then released with 
restriction enzymes BsrG1 and AgeI and cloned into similarly digested vector pHIS1525 
(MoBiTec), placing the gene under control of a xylose-inducible promoter.  Recombinant 
protein was expressed in B. megaterium and purified by sequential nickel affinity and 
gel filtration chromatography. Two mice were immunized bi-weekly by intraperitoneal 
-GTD. Three days after the third vaccination, 
splenocytes were harvested and fused to P3X63Ag8.6.5.3 myeloma cells using 
polyethylene glycol 1500 [167]. Hybridomas producing anti-TcdB-GTD MAbs were 
identified by ELISA, subcloned by limiting dilution, and purified by protein G 
immunoaffinity chromatography. 
 
Cell based cleavage assay   
HeLa cells were synchronized by cooling to 4 °C and then intoxicated with 10 nM 
TcdB, autoprocessing mutant, or buffer.  The cells were returned to 4 °C for 1 h, and 
then shifted to 37 °C for 50 min.  The cells were harvested and lysed, samples were 
boiled, and proteins were separated by SDS PAGE.  Samples were analyzed by 
Western with primary antibodies specific for the TcdB GTD, unglucosylated Rac1 (BD, 
610650), total Rac1 (Millipore, clone 23A8), and GAPDH (Santa Cruz Biotechnology, 
sc-25778).  Binding of an anti-mouse, HRP-conjugated secondary antibody (Jackson 
32 
 
ImmunoResearch Laboratories, 115-035-174) was detected with a LumiGLO kit (Cell 
Signaling) according to manufacturer’s instructions. 
  
In vitro glucosyltransferase assay   
Unless otherwise noted, 100 nM TcdB or TcdB glucosyltransferase mutants and 
2 uM Rac1 were mixed with 20 mM UDP-[14C]glucose (250 mCi/mmol, Perkin Elmer) in 
a total reaction volume of 10 uL.  The buffer contained 50 mM HEPES pH 7.5, 100 mM 
KCl, 1 mM MnCl2, 2 mM MgCl2, and 0.1 mg/mL BSA.  Reactions were incubated at 37 
°C for 1 h and stopped with the addition of loading buffer and boiling.  Proteins were 
separated by SDS PAGE, and glucosylation of Rac1 was detected by phosphorimaging.   
 
Kinetic assays of cytotoxic and cytopathic events   
HeLa cells were seeded in a black 96-well imaging plate (PerkinElmer) and 
incubated overnight.  Cells were pretreated with live/dead cell imaging dyes (Molecular 
Probes, R37601) and then treated with multiple concentrations of wild-type and mutant 
TcdB proteins.  Cells were imaged in an environment-controlled chamber (37 °C, 5% 
CO2) every 10 minutes over a 2 hour time using an Opera High-Throughput Confocal 
Screening Microscope and Peltier-cooled, confocal CCD cameras.  The percentage of 
dead cells and round cells was quantified over six fields for each concentration and time 
point using the Columbus Analysis software.  Dead cells were defined as red cells with 
an intensity greater than 450 relative units, and round cells were defined as having an 
area less than 500 um2 and a width-to-length ratio of less than 0.4. 
 
Porcine colonic explants   
 Colonic tissue was harvested from purpose-bred 25-35kg, male or female, York-
Landrace crossbred pigs.  Following an overnight fast and immediately after euthanasia, 
a midline incision was performed and 15 cm of distal colon proximal to the rectum was 
excised and placed in PBS.  The colon was opened, the luminal side was washed 3 x 5 
min in 1 mM DTT to remove the mucus, and 3 x 5 min in PBS prior to dissection. 
Individual tissue sections were placed in wells of a 24-well plate.  A nutrient buffer [132] 
containing (mM/liter): 122.0 NaCl, 2.0 CaCl2, 1.3 MgSO4, 5.0 KCl, 20.0 glucose, 25.0 
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NaHCO3 (pH 7.5) was pre-conditioned with HeLa cells overnight at 37 °C and used to 
dilute the toxins. Explants were treated with wild-type TcdB, mutant TcdB, staurosporine 
(100 uM, Enzo Life Sciences, ALX-380-014-C250) or nutrient buffer for 5 hours at 37 
°C.  The tissues were fixed with formalin for 56 h, washed in PBS, and transferred to 
cassettes.  The tissue blocks were then embedded in paraffin, and 4 μm sections were 
cut and stained with hematoxylin and eosin (H&E) by the Vanderbilt University 
Translational Pathology Shared Resource core.  Stained sections were coded and 
evaluated by six individuals, using a semi-quantitative injury scale: 0- no damage; 1-
superficial damage, damage limited to intact surface epithelial cells; 2-loss of up to 50% 
of surface epithelial cells or gland length, crypts intact; 3-loss of over 50% of surface 
epithelial cells and damage in greater than 50% of gland length.   An injury score was 
calculated as the mean score for sections evaluated seven times by six individuals.  
Statistical analysis was performed using a two-way ANOVA and Bonferroni’s test.  For 
keratin and caspase staining, sections were de-paraffinized with Histo-clear (National 
Diagnostics) and antigens were retrieved by citric acid. The sections were blocked with 
Serum-free protein block (Dako), stained with a rabbit anti-pan cytokeratin or anti-active 
caspase-3 antibody (Santa Cruz Biotechnology, sc-15367; Abcam, ab13847), and 
diluted in Dako’s antigen diluent with background reducing components overnight at 
4˚C.  The sections were washed with PBS and incubated for 1 hr at RT with an 
AlexaFluor 546 donkey anti-rabbit antibody (Invitrogen A10040).  The sections were 
washed with PBS and mounted with Prolong Gold with DAPI (Invitrogen).  H&E, pan-
cytokeratin, and caspase-3 stained sections were imaged using an Ariol SL-50 
(Epithelial Biology Center Imaging Core). 
 
Results 
 
TcdB induces necrosis in cultured epithelial cells  
The objective at the outset of this project was to conduct a high-throughput 
screen for small molecules that inhibit TcdB-mediated cell death. Our first goal was, 
therefore, to establish conditions for an assay that was sensitive and homogeneous. 
HeLa cells were seeded into 384 well plates and treated with TcdB at multiple 
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concentrations for varying lengths of time. Cells were then simultaneously assayed for 
caspase-3/7 activation and ATP levels using fluorescent and luminescent indicators, 
respectively.  At all concentrations and time points tested, TcdB failed to activate 
caspase-3 and -7, central regulators in apoptotic cell death (Figure 2.1A).  Conversely, 
staurosporine, a known inducer of apoptosis, triggered significant caspase-3/7 
activation at a 5 hour time point.  Since the result appeared to be in conflict with a 
previous report showing that TcdB-treatment of HeLa cells induced an increased rate of 
caspase-3 activity [150], we performed additional experiments using lower toxin 
concentrations, a 48 hour time point, and TcdA. We did not observe caspase-3/7 
activation in any of the cells treated with TcdB and only saw TcdA-induced caspase-3/7 
activation when the toxin was applied at concentrations of 100 nM (Figure 2.2A). While 
our initial experiments were performed with TcdB purified from a recombinant Bacillus 
megaterium expression system, we did not observe caspase-3/7 activation when we 
tested TcdB purified from C. difficile culture supernatants (Figure 2.2B). 
Despite the lack of caspase-3/7 activation, the TcdB treatments had a significant 
impact on cellular ATP levels (Figure 2.1B).   Decreases in ATP were observed after 
only 2.5 hours in cells treated with 1, 10, and 100 nM TcdB suggesting that these cells 
were no longer viable.  The effect is specific to TcdB, as TcdA only impacted the 
viability at concentrations of 100 nM at 24 hours (Figure 2.3A). While lower 
concentrations of TcdB can induce cell death after a 48 hour application, the effect does 
not appear to be dose dependent at the 48 hour time point (Figure 2.3A).  
In an attempt to correlate the viability indicators with cytopathic events, mock and 
TcdB treated cells were visualized by light microscopy.  At concentrations of 10 pM, a 
characteristic cytopathic (cell rounding) effect was observed. In contrast, cells treated 
with 10 nM TcdB for 2.5 hours had completely lost their membrane integrity (Figure 
2.1C).  The rapid loss of ATP and membrane integrity suggested that cells treated with 
nM concentrations of TcdB were dying by necrosis.  To further test this hypothesis, we 
assessed the effect of TcdB on LDH and HMGB1 release.  LDH release was apparent 
2.5 hours after intoxication and at an increased level after 8 hours (Figure 2.1D).  
Similar values for LDH release are observed when the cells are treated with TcdB from 
C. difficile supernatants (Figure 2.3B).   Notably, LDH release is only detectable at toxin  
35 
 
 
  
Figure 2.1. TcdB induces necrosis in epithelial cells.   A, TcdB does not induce caspase-3/7 activation in HeLa 
cells, as detected by a fluorescent indicator, Apo-One.  B, TcdB induces rapid death in HeLa cells, as detected by a 
luminescent indicator, CellTiterGlo. Caspase-3/7 activation and viability values represent the average of three 
experiments in which each condition was tested in triplicate.  The error bars indicate the standard deviation 
between three experiments. C, HeLa cells were synchronized and incubated with or without TcdB for 2.5 hours at 
37 °C.  A representative image obtained by light microscopy indicates rounding in cells treated with 10 pM TcdB 
and a loss of membrane integrity in cells treated with 10 nM TcdB. D, Extracellular LDH was detected in TcdB-
treated HeLa cells after 2.5 hours using a luminescence-based indicator, Cytotox-Glo.  Increased levels of LDH 
release were apparent after 8 hours.  LDH release values represent the average of three experiments in which 
three replicates were averaged.  Error bars indicate the standard deviation between the values obtained from the 
three experiments. E, HeLa cells were treated with a buffer control or 10 nM TcdB for 1 h and then fixed with 4% 
formaldehyde.  Cells were stained with an antibody specific for HMGB1 and an Alexa Fluor 488 anti-mouse 
antibody.  The cells were visualized with a LSM510 Confocal microscope.  The representative images show that 
HMGBI is released from the nucleus of HeLa cells when treated with 10 nM TcdB and remains nuclear in the 
untreated cells. 
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Figure 2.2.  TcdA activates caspase-3/7 while both recombinant and native TcdB do not.  
A, TcdB does not induce caspase-3/7 activation in HeLa cells, as detected by a fluorescent 
indicator, Apo-One, at 24 or 48 h.  TcdA, however, does induce caspase-3/7 activation at a 
concentration of 100 nM at 24 h and 10 and 100 nM at 48 h.  B, TcdB purified from C. difficile 
supernatant looks similar to TcdB purified from B. megaterium in that neither induce caspase-3/7 
activation.  Values represent the average of 3 independent experiments in which each condition 
was tested in triplicate.  Error bars represent the standard deviation of the average of the three 
independent experiments. 
 
Figure 2.3.  TcdB is more cytotoxic than 
TcdA, and the effects of native and 
recombinant TcdB on LDH release are 
similar.  A,  TcdB induces significant HeLa 
cell death, as detected by CellTiterGlo, in 24 
h at concentrations of 1, 10, and 100 nM.  At 
48 h, a loss of cell viability was observed at 
lower concentrations in a dose-independent 
fashion.  TcdA induces significant cell death 
at 24 h and 48 h at a concentration of 100 
nM.  B, TcdB purified from C. difficile and B. 
megaterium induce release of LDH starting 
at 2.5 h, with increased levels apparent after 
8 h of treatment. Values represent the 
average of 3 independent experiments in 
which each condition was tested in triplicate.  
Error bars represent the standard deviation 
of the three independent experiments. 
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concentrations above 0.1 nM, consistent with the cell death data obtained with an ATP 
indicator (Figure 2.1B). HMGB1 is a nuclear protein that is released into the cytoplasm 
when the cell is dying by necrosis. We found that at 10 nM TcdB, HMGB1 was released  
into the cytoplasm after 1 hour (Figure 2.1E). As a result of these studies, CellTiterGlo, 
the luminescent indicator of cellular ATP levels, was deemed the best indicator of cell 
viability for high throughput screening. The rapid loss of ATP and membrane integrity, 
the release of LDH and HMGB1, and the lack of caspase-3/7 activation all suggest 
necrosis is the mechanism of TcdB-mediated death in HeLa cells.  
  
Mutations in the autoprocessing domain active site and the cleavage site result in TcdB 
proteins with impaired autoprocessing activity in vitro and in cells   
We next generated autoprocessing-deficient mutants that could be used as 
negative controls in a secondary assay that would allow us to select for molecules that 
inhibit the autoprocessing activity of the toxin. Single amino acid point mutations were 
made in the TcdB autoprocessing active site (C698S, C698A, H653A, and D587N) and 
the cleavage site (L543A).  Proteins were expressed in the B. megaterium expression 
system and purified to homogeneity.  All mutants were tested for their in vitro 
autoprocessing activity (Figure 2.4A). TcdB autoprocessing can be induced with the 
addition of 1 uM InsP6, and the amount of processing increases as the concentration of 
InsP6 increases.  At all concentrations of InsP6, TcdB C698S, TcdB C698A, and TcdB 
H653A were completely inactive in autoprocessing, as detected by Coomassie-stained 
SDS PAGE (Figure 2.4A) and densitometry (Figure 2.4B).  TcdB D587N and TcdB 
L543A had residual cleavage activity, but were significantly cleavage-impaired.  
Cleavage of D587N was not induced until 100 uM InsP6 was added, and the amount of 
processed toxin was reduced.   
 We next wanted to confirm that the mutants were also defective for 
autoprocessing in the context of the cell. HeLa cells were treated with wild-type TcdB or 
autoprocessing deficient TcdB mutants for 50 min, lysed, and probed by Western blot 
using an anti-TcdBGTD antibody.  Free GTD was detected in cells treated with wild-type 
TcdB but was not detected in cells intoxicated with TcdB mutants (Figure 2.4C). The 
same lysates were probed with an antibody specific for unglucosylated Rac1.  Rac1 is 
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glucosylated even when the cells have been treated with autoprocessing mutants.  
These data suggest that in cells treated with TcdB autoprocessing mutants, the GTDs 
are being translocated into the cytosol, but they remain tethered to the endosome where 
glucosylation of Rac1 can still occur. 
 
 
 
 
 
Figure 2.4.  Mutations in the autoprocessing 
domain active site and the cleavage site result in 
TcdB proteins with impaired autoprocessing 
activity in vitro and in cells.  A, Autoprocessing 
was induced in vitro by incubating wild-type TcdB and 
TcdB mutants with multiple InsP6 concentrations and 
1 mM DTT at 37 °C.  After 2 hours, the proteins were 
subjected to SDS-PAGE and visualized with 
Coomassie stain. A representative series of gels is 
shown from experiments performed in triplicate. B, 
Three replicates of the experiments shown in panel A 
were quantified by densitometry.  Bands 
corresponding to TcdB 544-2366 were quantified and 
normalized to the band corresponding to TcdB 1-
2366 without InsP6.  Error bars reflect the standard 
deviation of the percent cleavage between three 
experiments.  The data indicate that wild-type TcdB 
autoproteolysis can be detected at concentrations of 
1 uM to 1 mM InsP6. By comparison, TcdB mutants 
C698S, C698A, and H653A were completely inactive 
for autoprocessing at all InsP6 concentrations.  The 
TcdB D587N and L543A had some residual activity, 
but autoprocessing activity was impaired relative to 
wild-type.  D, GTDs of autoprocessing mutants are 
not released in cells.  HeLa cells were synchronized 
for 30 minutes at 4 °C, then intoxicated with 10 nM 
toxin.  Intoxicated cells were incubated at 4 °C for an 
hour before being moved to 37 °C.  Cells were 
harvested after 50 minutes and cell lysates were 
prepared for SDS PAGE and Western blot. The blot 
was probed with antibodies against the TcdB GTD, 
unglucosylated Rac1, total Rac1, and GAPDH.  While 
release of the GTD in cells intoxicated with wild-type 
TcdB was detected, the free GTD was not detected in 
cells treated with autoprocessing deficient mutants.   
The absence of signal with an antibody that 
recognizes unglucosylated Rac1 suggests that the 
autoprocessing mutants are still able to modify Rac1 
in cells. 
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Autoprocessing mutants induce necrosis in cultured epithelial cells  
To test the hypothesis that small molecule inhibitors of TcdB autoprocessing 
could be detected in a cell based screen, we assessed cell viability in response to three 
of the TcdB autoprocessing mutants: TcdB C698S, TcdB C698A, and TcdB L543A. 
HeLa cells were treated for 2.5 hours with multiple concentrations of TcdB and the TcdB 
mutants, and viability was assessed using CellTiterGlo. Unexpectedly, the 
autoprocessing deficient mutants were found to induce cell death at concentrations 
comparable to TcdB (Figure 2.5A).  To test whether this response was unique to HeLa 
cells, we performed similar experiments with Caco2 cells, an epithelial cell line derived 
from human colon.  As with the HeLa cells, wild-type and autoprocessing deficient TcdB 
mutants induced a decrease in cellular ATP at similar concentrations in Caco2 cells 
(Figure 2.5B). Caspase-3/7 activation was not detected in HeLa cells treated for 25 
hours with autoprocessing deficient TcdB mutants (Figure 2.5C), and the amount of 
LDH released in HeLa cells treated with wild-type TcdB and the TcdB C698S, C698A, 
and L543A autoprocessing mutants was equivalent (Figure 2.5D).  Finally, HeLa cells 
were treated with 10 nM wild-type and mutant TcdB proteins in the presence of a 
live/dead cell indicator and imaged every 10 minutes over a 2 hour time course. A 
representative movie of what we observed is included in the supplemental material 
(Video S1). The percentage of dead cells quantified over six fields suggests that the 
kinetics of cell death are identical for the four proteins (Figure 2.6). Collectively, these 
data suggest autoprocessing is not required for TcdB-mediated necrosis in epithelial 
cells.     
 
TcdB induced necrosis is a glucosyltransferase independent process  
The idea that TcdB-induced necrosis did not require autoproteolytic release of 
the GTD suggested that the TcdB glucosyltransferase activity would also not be 
required for cytotoxicity.  To test this hypothesis, single amino acid point mutations were 
made in the glucosyltransferase active site (D270N, D270A, Y284A, W520A, and 
N384A) based on the crystal structure of the TcdB GTD bound to UDP-glucose [10]. 
Proteins were expressed in the B. megaterium expression system and purified to 
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homogeneity.  All mutants were tested for their in vitro glucosyltransferase activity in the 
presence of purified Rac1 and UDP[14C]glucose, and all were impaired relative to wild- 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5.  Autoprocessing mutants induce necrosis in epithelial cells.  A, Toxins 
were applied to HeLa cells at concentrations ranging from 0.1 pM to 100 nM, and viability 
was measured after 2.5 hours with CellTiterGlo.  B, Toxins were applied to Caco2 cells at 
concentrations ranging from 0.1 pM to 100 nM, and viability was measured after 18 hours 
with CellTiterGlo.  Percent viability was determined by normalizing the signal from treated 
cells to the signal from untreated cells.  Values reflect the average signal from three 
experiments in which each condition was tested in triplicate.  Error bars correspond to the 
standard deviation in the percent viability from the three experiments. C, Autoprocessing 
mutants did not induce caspase-3/7 activation after 25 hours.  D, Comparable levels of 
extracellular LDH were detected after 8 hours in HeLa cells treated with wild-type TcdB and 
TcdB autoprocessing mutants.  Caspase and LDH values represent the average of three 
experiments in which three replicates were averaged.  Error bars indicate the standard 
deviation between the values obtained from the three experiments. 
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type (Figure 2.7A). Of the five mutants, the TcdB D270N mutant showed the greatest 
defect in in vitro glucosyltransfer, with residual activity only evident in the highest 
concentrations of enzyme and substrate (Figure 2.7B).  Even with differences in the 
amount of residual activity, all five mutants were defective in the modification of Rac1 in 
cells (Figure 2.7C). Furthermore, all 5 mutants were capable of inducing a cytotoxic 
effect similar to that of wild-type TcdB when applied to HeLa cells (Figure 2.7D) and 
Caco-2 cells (data not shown).  We interpret these data to mean that the TcdB cytotoxic 
effect does not require the glucosyltransferase activity of the toxin.  
 
The low concentration cytopathic effect is functionally distinct from the high 
concentration cytotoxic effect  
The observation that TcdB autoprocessing mutants were able to glucosylate 
Rac1 in cells (Figure 2.4C) suggested that they would induce rearrangements in the 
actin cytoskeleton that result in the cytopathic ‘rounding’ phenotype.  To investigate this, 
HeLa cells were treated with multiple concentrations of wild-type and mutant TcdB 
proteins and imaged every 10 minutes over a 2 hour time course. The percentage of 
round cells was quantified over six fields for each concentration and time point. At a 10 
pM concentration, we observed similar rounding kinetics for TcdB and the three TcdB 
autoprocessing-deficient mutants (Figure 2.8A).  Differences in the kinetics of rounding  
Figure 2.6.  TcdB and TcdB autoprocessing 
mutants have the same cytotoxicity kinetics.  A, 
TcdB, TcdB C698S, TcdB C698A, and TcdB L543A 
at 10 nM induce HeLa cell death at similar rates, as 
detected by Live/Dead Cell Imaging dyes.  Values 
represent the number of red (dead) cells per total 
number of cells (red + green) over six image fields 
and were calculated using Columbus Analysis 
Software.  Dead cells were defined as having a red 
intensity greater than 500 relative units.  B, 
Representative pictures of TcdB treated cells at 0 
and 120 minutes.  Images were taken using an 
Opera High-Throughput Confocal Screening 
Microscope. 
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began to appear at a concentration of 100 fM (Figure 2.8B) but were not fully evident 
until the concentration of toxins was dropped to 1 fM (Figure 2.8C).  The full dataset 
collected at concentrations spanning 8 orders of magnitude and a movie of what we 
observed with 10 fM wild-type TcdB is included in the supplemental material (Figure 2.9 
and Video S2). While not required for cytotoxicity, autoprocessing and GTD release 
appear to be important for cytopathic processes that occur at very low concentrations.  
In HeLa cells, we see that at concentrations where cytopathic effects can be observed 
(1 fM-10 pM, Figure 2.8), the cells are not dead (Figure 2.5A).  These data provide a 
clear distinction between the cytotoxic and cytopathic effects induced by TcdB.   
Figure 2.7.  TcdB glucosyltransferase mutants 
cause epithelial cell death. A, TcdB and TcdB 
glucosyltransferase domain mutants (100 nM) were 
tested for their capacity to glucosylate purified Rac1 
(2 uM) in the presence of 20 mM UDP-[
14
C]-glucose 
over the course of 1 h. The proteins were resolved by 
SDS-PAGE, and the gels were analyzed by 
Phosphorimaging. B, TcdB D270N was tested with 
higher concentrations of both toxin and UDP-[
14
C]-
glucose.  Only at the highest concentrations of both 
toxin and UDP-[
14
C]-glucose is residual activity 
apparent.  C, Glucosyltransferase activity in HeLa 
cells, as determined by Western and an antibody 
specific for unglucosylated Rac1, also showed that 
the glucosyltransferase mutants are deficient in Rac1 
glucosylation, though levels of impairment are varied.  
Again, D270N was the most deficient of the mutants.  
D, Wild-type TcdB and the TcdB glucosyltransferase 
mutants induced comparable levels of HeLa cell 
death, as determined by CellTiterGlo, after 2.5 h of 
treatment.  Percent viability was determined by 
normalizing the signal from treated cells to the signal 
from untreated cells.  Values reflect the average 
signal from three experiments in which each 
condition was tested in triplicate.  Error bars 
correspond to the standard deviation in the percent 
viability from the three experiments. 
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Figure 2.8. TcdB and TcdB autoprocessing mutants cause cell rounding with 
concentration dependent kinetics.  HeLa cells were treated with multiple 
concentrations of wild-type and mutant TcdB proteins and imaged every 10 minutes 
over a 2 hour time course. The percentage of round cells was quantified over six 
fields for each concentration and time point.  The kinetics of rounding induced by 
TcdB and the TcdB autoprocessing mutants is shown at concentrations of A, 10 pM.  
B, 100 fM and C, 1 fM. D, Representative images of cells treated with 1 fM TcdB and  
TcdB autoprocessing mutants for 50 minutes.  Green cells are alive; red cells are 
dead.  Images were collected with an Opera High-Throughput Confocal Screening 
Microscope in an environment-controlled chamber at 37 °C, 5% CO2.  Round cells 
were defined as having an area less than 500 um
2
 and a width-to-length ratio of less 
than 0.4.  Analysis was performed using Columbus Analysis software. 
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TcdB and TcdB C698A cause epithelial damage in porcine colonic explants  
The distinction between cytopathic and cytotoxic events in cell culture led us to 
question if either event might correlate with disease pathology.  Since the formation of 
necrotic lesions in the colon is a hallmark of CDI pathology, we sought to determine the 
concentration of toxin required to induce these effects and whether autoprocessing was 
required. Porcine colonic explants were incubated with multiple concentrations of toxin 
for 5 hours.  The tissue was fixed with formalin, embedded in paraffin, and sections 
were stained with H&E (Figure 2.10A). The slides were scored in a blinded fashion and 
given a score (0-3) to reflect the level of epithelial damage (Figure 2.10B).  Damage 
ranged from a mostly intact surface epithelium to mucosal loss of 50% or greater in the 
depth of colonic crypts. The scores indicated a loss of surface epithelium in tissue 
treated for 5 hours with 10 nM TcdB and TcdB C698A.  There was little damage in 
tissues treated with a buffer control or in tissues treated with wild-type TcdB and TcdB 
C698A at a concentration of 10 pM.  Statistical analysis by two-way ANOVA revealed a 
significant difference in scores for tissues treated with the toxins over the range of 
concentrations (p < 0.001), while there was no statistical difference between tissues 
treated with wild-type TcdB and TcdB C698A.  A subsequent Bonferroni’s test revealed 
that scores given to tissue treated with 10 nM TcdB and 10 nM TcdB C698A were 
significantly different from scores given to tissue treated with 10 pM TcdB and 10 pM 
TcdB C698A (p < 0.001).  The tissues were stained with an anti-pan cytokeratin 
antibody to confirm the keratin positive cells at the luminal surface of the colon were 
disrupted (Figure 2.10C) and an anti-activated caspase-3 antibody to confirm that the 
toxin treatment did not induce an apoptotic response (Figure 2.10D).  The data reveal a  
Figure 2.9.  TcdB and TcdB autoprocessing mutants have different cytopathic kinetics at 1 fM.  
HeLa cells were treated with multiple concentrations of wild-type and mutant TcdB proteins and 
imaged every 10 minutes over a 2 hour time course. The percentage of round cells was quantified 
over six fields for each concentration and time point.  Percent rounded cells induced by TcdB and 
autoprocessing mutants is shown at concentrations of A, 10 nM, B, 1 nM, C, 100 pM, D, 10 pM, E, 1 
pM, F, 100 fM, G, 10 fM, and H, 1 fM.  Differences in the rounding kinetics between TcdB and 
autoprocessing mutants begin to appear at a concentration of 100 fM and are clearly distinct at 1 fM. 
Images were collected with an Opera High-Throughput Confocal Screening Microscope in an 
environment-controlled chamber at 37 °C, 5% CO2.  Round cells were defined as having an area less 
than 500 um
2
 and a width-to-length ratio greater than 0.4. Analysis was performed using Columbus 
Analysis software. 
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Figure 2.10.  TcdB and TcdB C698A cause epithelial damage in porcine colonic explants.   
Porcine colonic explants were treated with 1 mM DTT to remove the mucus layer, washed with PBS, 
and incubated with toxin at 37 °C for 5 hours.  A, Tissue sections were stained with H&E. B, The H&E 
slides were scored in a blinded fashion using a semi-quantitative injury scale: 0- no damage; 1-
superficial damage, damage limited to intact surface epithelial cells; 2-loss of up to 50% of surface 
epithelial cells or gland length, crypts intact; 3-loss of over 50% of surface epithelial cells and damage 
in greater than 50% of gland length.   An injury score was calculated as the mean score for sections 
analyzed seven times by six individuals.  Statistical analysis was performed using a two-way ANOVA 
and post-hoc tests.  These analyses revealed a significant difference in the scores given to tissues 
treated with the toxins over the range of concentrations (p < 0.001), while there was no statistical 
difference between tissues treated with TcdB and TcdB C698A.  A subsequent Bonferroni’s test 
revealed that scores given to tissue treated with 10 nM TcdB and 10 nM TcdB C698A were 
significantly different from scores given to tissue treated with 10 pM TcdB or 10 pM TcdB C698A (p < 
0.001).  Error bars correspond to the standard deviation between the seven scores.  C, The sections 
were also stained with an anti-pan keratin and D, anti-active caspase-3 antibody. Representative 
images of H&E, pan-cytokeratin, and active caspase-3 staining (white – pan-cytokeratin/active 
caspase-3, green – DAPI) show significant damage to the epithelium of the colon at concentrations of 
TcdB and TcdB C698A that kill cells (10 nM).  At concentrations that induce rounding but not death in 
cultured cells (10 pM), there was no significant damage to the tissue surface cells.  Caspase-3 
activation was not detected at levels above background in any of the TcdB-treated tissues.  
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correlation between the concentration of toxin required to kill epithelial cells in culture 
with the concentration required to disrupt epithelial integrity in colonic tissue and 
indicate that autoprocessing is not required for tissue damage.   
 
 
Discussion 
 
TcdB is a multi-functional protein with a central role in CDI pathogenesis. Our 
goal at the outset of this study was to conduct a screen for small molecule inhibitors that 
could aid in the dissection of the TcdB mechanism and the generation of new leads for 
therapeutic intervention.  Our strategy was to combine a cell-based phenotypic screen 
with target-specific secondary assays. In the course of setting up our screening assays, 
we made two unexpected observations that warranted further investigation. 
 First, in contrast to a previous report [150], TcdB did not trigger the induction of 
apoptosis in cultured epithelial cells as measured by caspase-3/7 activation (Figure 
2.1A, 2.2).  Since there was an overlap in the cells, concentration of toxin, and 
timepoints used for analysis, we are left to speculate that the difference stems from 
advances in the detection reagent.   The newer reagent for detecting caspase-3/7 
activation allows one to directly quantitate the relative quantity of activated caspase-3/7 
as opposed to the overall rate of caspase activity.  
While TcdB-treatment did not induce the activation of caspase-3/7, the rapid ATP 
depletion observed in both HeLa (Figure 2.1B, 2.5A, 2.3A) and Caco2 (Figure 2.5B) 
cells suggested that the mechanism of TcdB-induced cell death was likely necrosis. The 
observed loss of membrane integrity (Figure 2.1C), rapid LDH (Figure 2.1D, 2.3B), and 
HMGB1 release (Figure 2.1E) support this conclusion.   
We next questioned whether a cell-based assay for small molecule inhibitors of 
TcdB-induced necrosis would allow us to detect molecules that interfered with 
autoprocessing. We were particularly interested in targeting the autoprocessing activity 
of the toxin since, in theory, one could identify molecules that either activate (e.g. InsP6) 
or inhibit the function of the cysteine protease domain.  We generated five TcdB point 
mutants in which key residues of the cysteine protease active site or cleavage site were 
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mutated.  Three of these mutations, C698S, C698A, and L543A, rendered TcdB non-
functional for InsP6-induced autoprocessing in an in vitro assay, even when InsP6 was 
added at a 1 mM concentration (Figure 2.4A, 2.4B). The mutants were also defective for 
autoprocessing in the context of cells since free GTD could be detected in cells treated 
with wild-type TcdB but not in cells treated with the autoprocessing mutants (Figure 
2.4C).  While we cannot rule out the possibility of an alternate cleavage mechanism that 
results in a quantity of free GTD that is less than the detection limit of the assay, the 
free GTD concentration generated from such a mechanism would be too small to 
account for the identical cytotoxicity profiles observed in Figures 2.5A and 2.5B.  
The unexpected observation that cytotoxicity does not require autoproteolytic 
release of the GTD led us to directly test whether the glucosyltransferase activity of the 
toxin was required (Figure 2.7).  We generated five single amino acid point mutants of 
TcdB that differed in their residual glucosyltransferase activities in vitro (Figure 2.7A, 
2.7B).  Despite the different enzyme activity levels, all were significantly impaired 
relative to wild-type TcdB in their capacity to modify Rac1 in cells (Figure 2.7C), and all 
were comparable to wild-type TcdB in their cytotoxic effects (Figure 2.7D).  These data 
are consistent with the observation that autoprocessing is not required and suggest that 
the cytotoxic response to TcdB is triggered by an event upstream of GTD release.  
While not required for cytotoxicity, autoprocessing and GTD release are 
important for cytopathic processes that occur at low concentrations [3,32,35,103,104].  
Our data are consistent with these previous reports and indicate differences in rounding 
kinetics emerging at concentrations of 100 fM (Figure 2.8C and 2.9).  While our Western 
experiment indicated TcdB autoprocessing mutants were still able to modify Rac1 in 
cells (Figure 2.4C), a similar observation has been made for a non-cleavable form of 
TcdA and is thought to reflect continuous vesicle trafficking and an exchange of 
membranous compartments that allow the uncleaved toxin to come into contact with the 
membrane-bound GTPases [105].  This capacity to modify Rac1 while still tethered to 
the endosomal membrane presumably accounts for the similar rounding kinetics that we 
observed when the TcdB autoprocessing mutants were applied to HeLa cells at 
concentrations of 1 pM and higher (Figure 2.8A, 2.9).  
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The concentrations of TcdB needed to induce cytopathic effects (≤ 1 fM, Figure 
2.9) are significantly lower than what is required to induce the cytotoxic effect (1 nM, 
Figure 2.5).  At a concentration of 10 pM TcdB, the cells are clearly round (Figure 2.8A) 
but not dead (Figure 2.5). The distinction between cytopathic and cytotoxic events in 
cell culture raises the question of whether either process correlates with mechanisms of 
pathology observed in the host.  To address this question, we decided to test what 
concentration of toxin was required to induce epithelial cell damage in colonic tissue 
explants. Visual assessment of H&E stained colonic tissue integrity in a blinded fashion 
indicated damage with treatments of 10 nM TcdB but not with 10 pM TcdB (Figure 
2.10). Similar observations were made with the TcdB C698A mutant suggesting that the 
damage that occurs to colonic tissue in response to TcdB does not depend on the 
autoprocessing activity.  Pan-cytokeratin staining confirmed that the cells on the luminal 
surface of the tissue remained intact in the presence of 10 pM TcdB or TcdB C698A but 
were being disrupted in samples treated with 10 nM TcdB, 10 nM TcdB C698A, or 100 
uM staurosporine. The staurosporine control revealed strong caspase-3 activation into 
the crypts (Figure 2.10D).  The untreated control tissue demonstrated a low level of 
caspase-3 activation in the cells on the luminal surface and strong activation in single 
cells coming off the surface of the tissue. Tissues treated with 10 pM TcdB and TcdB 
C698A showed caspase-3 activation levels similar to those of the untreated tissue.  
Tissue treated with 10 nM TcdB or TcdB C698A demonstrated even lower levels of 
caspase-3 activation, presumably because the cells on the luminal surface have been 
shed.  Unlike the untreated, staurosporine-treated, and 10 pM TcdB-treated tissues, 
caspase-3 activation was generally not observed in the cells that were in the process of 
being shed in tissues treated with 10 nM TcdB or TcdB C698A (Figure 2.10D).  This 
suggests that tissue damage is not only independent of autoprocessing activity, but also 
not likely due to apoptosis. 
The phenotypic differences with concentration led us to wonder what 
concentration of toxin is present in the colons of individuals experiencing the symptoms 
of CDI.   
We found only one published report, where TcdB was quantitated using a real-
time cell analysis system [168].  In this report, the TcdB concentrations in stool samples 
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from 10 patients experiencing mild to severe symptoms of CDI ranged from 4.9 pM to 
413 pM with a mean concentration of 146 pM.  Presumably, the concentration of TcdB 
would be much higher at the colonic epithelium prior to dilution by diarrhea.  Of note, the 
average TcdB concentration in samples from 9 individuals who were not experiencing 
CDI symptoms was 1 pM, with a range of 0.1 pM to 3.3 pM.  This analysis suggests that 
the cytotoxic effects observed in cells and tissues treated with 1 to 10 nM TcdB are 
better correlated with pathology than the cytopathic effects that are induced at 1 fM 
concentrations. 
Our data suggest that inhibiting TcdB autoprocessing will not prevent the colonic 
tissue damage observed in C. difficile associated diseases. However, while the colonic 
epithelium is the primary barrier separating C. difficile from the host, it is possible that 
the autoprocessing function of TcdB is important in another setting relevant to 
pathogenesis. For example, the colonic explant model used in this study does not 
account for the impact of the toxins on inflammation or the potential impact of an 
anaerobic environment. Evaluating the effect of autoprocessing- and 
glucosyltransferase-deficient toxins in an animal model of C. difficile infection therefore 
represents a priority for future studies.  In addition, it will be important to define the 
mechanism of TcdB-mediated necrosis in cells and tissue.  Relevant comparisons may 
come from the study of other toxins.  For example, the Bordetella pertussis adenylate 
cyclase (AC) toxin is known to have multiple mechanisms that contribute to cytotoxicity 
[169].  Identifying the autoprocessing- and glucosyltransferase-dependent and –
independent aspects of TcdB-mediated pathology represents an exciting path for future 
study.    
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CHAPTER III 
 
 
CLOSTRIDIUM DIFFICILE TOXINS A AND B CAUSE COLONIC TISSUE DAMAGE 
BY DISTINCT MECHANISMS 
 
 
Introduction 
 
  Clostridium difficile is the most common cause of antibiotic-associated diarrhea in 
the United States and has been steadily increasing in prevalence and severity over the 
last 15 years [162,170,171].  Symptoms of C. difficile infection (CDI) can range from 
mild diarrhea to pseudomembranous colitis, and hallmarks of the disease include 
neutrophil infiltration, fluid release, and necrotic lesions in the colonic epithelium 
[34,172].  The bacteria produce two main virulence factors, large toxins called TcdA and 
TcdB [63,64].   
The respective function and relative importance of each toxin in pathogenesis 
has been an active topic of investigation.  Genetic knockout experiments in C. difficile 
have shown both toxins are important for disease pathology, although TcdB alone is 
sufficient to cause death in the hamster model [63,64].  For many years, TcdA and TcdB 
have been thought to act synergistically with TcdA acting as an enterotoxin and TcdB 
acting as a cytotoxin [123,129]. The general term enterotoxin refers to the capacity of 
TcdA to induce inflammation, cytokine release, and fluid secretion in animal intoxication 
models [67-69].  While TcdB does not always induce these same phenotypes in animal 
models, it has been shown to disrupt the integrity of the epithelial structure in both 
explant and xenograft models [132,133].   TcdB is also notably more potent as a 
cytotoxin in cell culture models [123,129-131].  
The toxins have an N-terminal glucosyltransferase domain (GTD) that is 
delivered into the host cytosol by the C-terminal portion of the protein [102,163].  The 
GTD has been shown to target and inactivate a number of Rho-family GTPases, This 
inactivation has been linked to a cell ‘rounding’ or cytopathic effect (CPE) [108-110,173] 
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and to an apoptotic cytotoxic effect [9,20,21,126,142-145,150,151].   In most reports, 
the cytotoxic effects of TcdA in tissue culture models are not realized until more than 24 
hours post intoxication [9,20,105,115,145,174]. TcdB also induces a 
glucosyltransferase-independent necrosis that is mediated by the assembly and 
activation of the NADPH oxidase (NOX) complex, subsequently producing high levels of 
reactive oxygen species (ROS) [100,174-177]. These observations were made at 
nanomolar concentrations in both tissue culture and colonic explant models.  
In this study, we wanted to investigate the mechanisms and pathological 
outcome of both TcdA and TcdB intoxication under comparable conditions.  Using a 
colonic explant model, we found that TcdA causes damage to tissue at the same 
concentrations as TcdB.  Since we have previously been unable to recapitulate these 
observations in tissue culture systems, we reasoned that the anti-apoptotic mutations of 
transformed cell lines may be preventing pathologically relevant outcomes of TcdA 
intoxication.  Therefore, we wanted to find a non-transformed cell line that would allow 
us to study TcdA mechanisms of cell death in a convenient, accurate, and relevant 
model system that recapitulated our observations in tissue.  Young adult mouse colonic 
(YAMC) epithelial cells are derived from the Immortomouse which expresses a 
temperature sensitive simian virus 40 (SV40) T-antigen that suppresses p53 [178].  The 
cells can be carried as an anti-apoptotic cell line at the permissive temperature of 33 °C, 
and then upon shifting to the non-permissive temperature of 37 °C, YAMC cells behave 
as primary cells with an intact p53 pathway able to undergo normal apoptosis.  Using 
this tool, we were able to investigate the effects of TcdA and TcdB side-by-side in the 
same cell line at the same time points with the same assay readouts.  Our observations 
provide an opportunity to unify the many, seemingly conflicting, reports describing the 
mechanisms by which TcdA and TcdB cause cell death in epithelial cells.   
 
Methods 
 
Recombinant protein expression and purification 
The glucosyltransferase domain double point mutation (TcdA D285/287N and 
TcdB D286/288N) plasmids were made using the TcdA and TcdB parent plasmids [5] 
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according to the QuickChange protocol (Stratagene).  Recombinant TcdA, TcdA 
D285/287N, TcdB, and TcdB D286/288N proteins were expressed in B. megaterium 
and purified as previously described[5]. 
 
 YAMC cell culture and viability assays   
YAMC cells were maintained in RPMI-1640 supplemented with 5% FBS, 1 mg/ml 
insulin, 10 uM alpha-thioglycerol, 1 uM hydrocortisone, and 5 U/ml mouse interferon 
gamma.  Cells were carried at 33 C with 5% CO2. For assays performed at 37 C, cells 
were plated and incubated at 37 C with 5% CO2 overnight prior to intoxication. Viability 
was measured at the indicated concentrations and timepoints using the CellTiterGlo 
Luminescent Cell Viability Assay (Promega, G7573).  LDH release indicative of necrosis 
was quantified using CytoToxGlo (Promega, G9290).  Apoptosis was assessed by 
measuring active caspase 3 and 7 using Apo-ONE Homogeneous Caspase-3/7 Assay 
(Promega, G7792).  ROS production was assayed with Carboxy-H2DCFDA (Life 
Technologies, C400) as previously described [175]. 
 
Colonic explants  
Animal husbandry and experimental procedures related to the porcine colonic 
explants were performed in accordance with the Vanderbilt University Institutional 
Animal Care and Use Committee (IACUC) policy.  Discarded colon tissues were 
obtained from pigs following euthanization at the end of IACUC-approved animal use 
protocols and prepared for intoxication as previously described[174].  Human colonic 
tissue was obtained by the Cooperative Human Tissue Network from consented, de-
identified donors under IRB approved protocol 031078.  Tissue was challenged with 10 
nM TcdA, TcdB, TcdA D285/287N, or TcdB D286/288N for 5 h at 37 °C. Sections were 
cut by the Vanderbilt University Translational Pathology Shared Resource core. The 
H&E staining and scoring of tissues was performed as previously described [174].  H&E 
stained images were obtained with the Ariol SL-50 (Epithelial Biology Center Imaging 
Core).  Caspase 3 and ROS staining of tissues were done as previously described 
[174,175].  All slides stained with fluorescent markers were analyzed with an LSM 510 
Confocal microscope. 
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Statistical Analysis   
Statistical analysis was performed using a two-way ANOVA and post-hoc test in 
GraphPad Prism.  Two-tailed, paired student’s t-tests were performed using Excel.   
 
Results 
 
TcdA causes damage to colonic tissue  
Freshly excised colonic explants were intoxicated with TcdA and TcdB at a range 
of concentrations (10 pM to 100 nM) for 5 hours, and damage to the colonic epithelium 
was assessed in H&E stained tissue sections using a semi-quantitative injury scale 
(Figure 3.1A). The tissue damage induced by the toxins is dose-dependent and 
significant at concentrations ≥ 100 pM (Figure 3.1B).  Statistical analysis by a two-way 
ANOVA revealed there was no significant difference between pathology scores of tissue 
intoxicated with TcdA and TcdB at any concentration tested (Figure 3.1B).  These 
results demonstrate that TcdA causes damage to tissue within a five hour time frame at 
similar doses as TcdB.    
 
TcdA induces a robust cell death in conditionally immortalized cells  
The explant model is informative in that we can establish similar potencies 
between TcdA and TcdB, but H&E staining does not allow the delineation of 
mechanistic detail by which damage is occurring.  For example, if the toxins cause 
damage with similar potencies in tissue, why do we not observe the same phenotype in 
tissue culture models?  We hypothesized that the lack of rapid TcdA-induced cell death 
in typical tissue culture models was due to mutations in the apoptotic pathways of many 
transformed cell lines. In order to test our hypothesis, we obtained YAMC cells, a 
conditionally immortalized cell line with temperature-dependent p53 function. YAMC 
cells were challenged with the TcdA and TcdB toxins at both the permissive and non-
permissive temperatures, and cell death was quantified using CellTiterGlo, an ATP 
sensitive viability indicator. Consistent with what is observed in transformed cell lines, 
TcdA does not induce appreciable cell death at the permissive temperature of 33 °C, 
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where p53 is inactivated (Figure 3.2A).  TcdB does not cause cell death at 
concentrations ≤ 10 pM but kills cells efficiently at concentrations ≥ 100 pM, consistent 
with our previous observations in transformed HeLa and Caco2 cell lines [174].  
 
 
 
Upon shifting to 37 °C and allowing normal p53 expression, however, we 
detected a drastically different phenotype. Consistent with observations in our colonic 
explant model, TcdA caused cytotoxicity in YAMC cells across a wide concentration 
Figure 3.1. TcdA causes damage to 
colonic tissue.  A, Porcine colonic 
explants were intoxicated with the 
indicated concentration of toxin and 
incubated at 37 °C for 5 hours. Slides 
were stained with H&E. B, Tissue 
sections were scored in a blinded 
fashion by 3 pathologists using a 
semi-quantitative injury scale: 0-no 
damage; 1-superficial damage, 
damage limited to intact surface 
epithelial cells; 2-loss of up to 50 % of 
surface epithelial cells or gland length, 
crypts intact; 3-loss of over 50% of 
surface epithelial cells and damage in 
greater than 50% of gland length.  The 
scores represent the average of 
triplicate scores of at least 4 different 
experiments.  Error bars represent the 
standard deviation of all scores given 
in all experiments.  The data were 
analyzed by two-way ANOVA, and at 
all concentrations, TcdA and TcdB 
were not statistically different.  
Student’s t-tests were performed 
between each toxin at each 
concentration and the mock treated 
tissue and found every concentration 
except 10 pM to have significant 
pathological damage at p < 0.001, 
represented by the asterisk. 
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range (100 nM to 10 fM, Figure 3.2B). These results suggest that when cells are 
intoxicated with TcdA, the mechanism of cell death may be dependent on the p53 
pathway.    
Interestingly, we also observed differences in TcdB-induced cell death when 
comparing the two cellular states.  In cells at 33 °C, where p53 function is disrupted, we 
detected significant cell death when we used higher concentrations (100 nM to 100 pM) 
of TcdB. At lower concentrations, starting at 10 pM, however, the cells were viable 
(Figure 3.2A).  We do not observe this change in cell viability at 37 °C, where p53 
function is not disrupted.  TcdB causes cytotoxicity at all concentrations assayed at 37 
°C, suggesting that the cell death induced by TcdB at lower concentrations (≤ 10 pM) is 
dependent upon the p53 pathway.  
 
 
Figure 3.2.  TcdA induced cell death 
of conditionally immortalized cells is 
p53 dependent.  YAMCs were seeded 
in a 96 well plate and incubated 
overnight at either A, 33 °C or B, 37 °C.  
Cells were intoxicated as indicated and 
incubated at their respective 
temperatures for 18 h.  Cell viability 
was determined using CellTiterGlo, an 
ATP sensitive, luminescent viability 
indicator.  Relative survival was 
calculated by normalizing the treated 
samples to untreated samples.  Data 
represent the average of three 
experiments performed in triplicate.  
Error bars represent the standard 
deviation of the averages of the 3 
experiments. Asterisks represent a 
statistical difference between TcdA and 
TcdB with a p-value of  p < 0.0001  by 
two-way ANOVA.  There is no 
statistical difference between TcdA and 
TcdB between 10 pM and 100 fM by 
two-way ANOVA.  At 10 fM, a 
significant difference in potency 
becomes apparent when analyzed by a 
student’s t-test, paired, two-tailed, and 
a p-value < 0.0001. 
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TcdA induces cell death by a mechanism distinct from TcdB at higher toxin 
concentrations   
The difference in killing induced by TcdA and TcdB observed at high 
concentrations suggests they are killing cells by distinct mechanisms.  We expected 
TcdB to induce ROS-driven necrosis at these higher concentrations based on our 
previous work [175]. ROS production in response to each toxin was monitored in YAMC 
cells using a fluorescent ROS reporter (Figure 3.3A).  TcdB induced the production of 
high levels of ROS at higher concentrations (≥ 100 pM), where we have previously 
observed necrosis, but not at toxin concentrations below 100 pM.  This observation is 
consistent with the mechanistic switch noted in Figure 2 over the same concentration 
range.  TcdA induced a small amount of ROS production at 100 nM, though it remains 
significantly different from the signal induced by TcdB (Figure 3.3A).   
We next wanted to see if the cells were dying by a necrotic mechanism using a 
lactose dehydrogenase (LDH) indicator as a quantitative measure for the loss of cell 
membrane integrity, a hallmark of necrosis (Figure 3.3B,C).  LDH signal in response to 
TcdA was not detected until 24 hours after intoxication (Figure 3.3B), which may reflect 
necrosis secondary to apoptosis.  In contrast to TcdA, and consistent with our previous 
observations, we detected rapid necrotic cell death in response to TcdB at 
concentrations ≥100 pM (Figure 3.3C).  We detected a loss of membrane integrity as 
early as 2 hours after cells were challenged with TcdB (Figure 3.3C).  LDH signal 
increased in cells treated with high concentrations (100 pM to 100 nM) of toxin for up to 
8 hours post intoxication (Figure 3.3C).  At these higher concentrations, at 2, 4, and 8 
hours, the LDH signal induced by TcdB was significantly different from that induced by 
TcdA.  Concentrations below 100 pM did not demonstrate an appreciable rise in LDH 
levels at the 2, 4, or 8 hour time points assayed and were not significantly different from 
the signal produced from cells intoxicated with TcdA.  However, an increase in LDH 
signal at lower concentrations was detected at 24 h post-intoxication with TcdB, again 
suggesting secondary necrosis (Figure 3.3C).  Notably, there was no significant 
difference in the LDH signal in cells treated with TcdA and TcdB at any concentration at 
the 24 hour time point.  The correlation of ROS production and LDH release in response 
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to higher concentrations (≥ 100 pM) of TcdB indicates a necrotic cell death.  The 
absence of ROS and delayed LDH signal in response to TcdA intoxication suggests that 
TcdA is not inducing necrosis, demonstrating that TcdA at all concentrations and TcdB 
at concentrations 100 pM and above are causing cell death by different mechanisms. 
 
 
 
 
 
 
 
 
 
Figure 3.3.  TcdA induces cell death by a mechanism different from TcdB.   YAMC cells were seeded into multiwell 
plates and incubated at 37 °C overnight.  The cells were then intoxicated with indicated concentrations of toxin and 
incubated at 37 °C.  A, YAMCs were tested for ROS production in response to TcdA (white bars, 24 h) or TcdB (black 
bars, 6 h) using a fluorescent ROS reporter.  Statistical analysis by two-way ANOVA revealed TcdA and TcdB were 
significantly different at all concentrations with p < 0.0001.  The cells were then tested for LDH release, using 
CellToxGlo, in response to B, TcdA or C, TcdB at the indicated time points.  Data in panels B and C were analyzed by 
two-way ANOVA at each time point.  At 2, 4, and 8 h, there was a significant difference between TcdA and TcdB at 
concentrations ≥100 pM.  There was no significant difference at concentrations ≤10 pM.  At 24 h, two-way ANOVA 
revealed no significant difference between TcdA and TcdB at any concentration tested.  D, YAMCs were also tested for 
activated caspase-3/7 using Apo-ONE, in response to TcdA (white bars), TcdA D285/287N (light gray bars), TcdB (black 
bars), or TcdB D286/288N (dark gray bars).  Three separate two-way ANOVAs were used to analyze the data in panel 
D.  The first revealed a significant difference between TcdA and TcdB at concentrations ≥100 pM with p < 0.0001.  
There was no significant difference at concentrations ≤10 pM.  The second two-way ANOVA revealed a significant 
difference between TcdA and TcdA D285/287N at all concentrations with p < 0.0001.  The third two-way ANOVA 
showed no significant difference between TcdB and TcdB D286/288N at concentrations ≥100 pM.  At concentrations 
≤10 pM, there was a significant difference between TcdB and TcdB D286/288N with p < 0.01.  In all panels, data 
represent the average of 3 experiments performed in triplicate and error bars represent the standard deviation between 
the 3 experiments. 
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Given the importance of an intact p53 pathway (Figure 3.2), the absence of ROS 
production (Figure 3.3A), and the observation that TcdA and low concentrations of TcdB 
were not inducing early LDH release (Figure 3.3B and 3.3C), we chose to investigate 
apoptosis as a possible mechanism of cell death induced by TcdA and lower TcdB 
concentrations.  While it is often reported that TcdA and TcdB induce an apoptotic cell 
death, we sought to provide a direct link between apoptotic markers and viability data.  
As reported in the literature, apoptosis in response to the toxins is thought to be 
dependent upon glucosyltransferase activity and subsequent GTPase inactivation 
[20,126,146-148,150,151,179,180].  To test this, we used an active caspase-3/7 
indicator to detect apoptosis in YAMC cells challenged with TcdA, TcdB, and their 
respective glucosyltransferase mutants (Figure 3.3D).  We detected a robust and dose-
dependent caspase-3/7 activation in response to TcdA.  The dose-dependence of 
caspase-3/7 activation correlates with the dose-dependent loss in cell viability we 
observed at 37 °C (Figure 3.2B).  The glucosyltransferase mutant, TcdA D285/287N, 
seemed to have some residual activity at 100 nM, activating caspase-3/7, but showed 
very little activity at the other concentrations tested (Figure 3.3D).  When the cells were 
challenged with higher, necrotic concentrations (≥ 100 pM) of TcdB, very little caspase 
activation was detected.  At concentrations of 10 pM and lower, however, we begin to 
detect appreciable caspase-3/7 activation.  Notably, the TcdB glucosyltransferase 
mutant, TcdB D286/288N, did not activate caspase-3/7 at any concentration tested 
(Figure 3.3D).  These data are consistent with previous reports and suggest that TcdA 
induces a glucosyltransferase-dependent, apoptotic cell death.  Also, at lower 
concentrations (≤ 10 pM) where necrosis is not observed, TcdB can induce a 
glucosyltransferase-dependent, apoptotic cell death, providing empirically derived 
support for TcdB utilizing a dose-dependent mechanistic switch.   
 
TcdA induces glucosyltransferase-dependent caspase-3 activation, while TcdB induces 
glucosyltransferase-independent ROS production in colonic tissue   
We next wanted to test whether our observations that TcdA and TcdB were 
inducing cell death by different mechanisms at higher concentrations in YAMC cells 
could also be observed in colonic explants.  We intoxicated tissue with 10 nM TcdA and 
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TcdB and their corresponding glucosyltransferase deficient mutants and assessed 
epithelial damage in H&E stained sections (Figure 3.4A).  Consistent with previous 
experiments, TcdA and TcdB cause epithelial damage at a concentration of 10 nM.  
TcdA D285/287N does not cause epithelial damage whereas TcdB D286/288N is 
equipotent to TcdB on colonic tissue.  These data are congruent with our observations 
in YAMC cells (Figure 3.3).  TcdA induced cell death and tissue damage is dependent 
upon the glucosyltransferase activity, while TcdB induced damage is independent of 
glucosyltransferase activity at a concentration of 10 nM.   
We also wanted to test the colonic tissue for ROS production and evidence of an 
apoptotic cell death in response to the toxins, using a fluorescent indicator and an 
antibody specific for active caspase-3, respectively.  Consistent with previous 
observations, we detected ROS in colonic explants treated with TcdB and TcdB 
D286/288N, but not in response to TcdA or TcdA D285/287N (Figure 3.4B).  We 
detected a robust active caspase-3 signal in tissue treated with TcdA (Figure 3.4C).  
While there was a low amount of detectable signal in tissue treated with TcdA 
D285/287N, it is much less than that induced by TcdA.  There was very little active 
caspase-3/7 signal in tissue treated with TcdB or TcdB D286/288N.  Together, these 
data support our observations in YAMC cells and suggest that TcdA and TcdB induce 
cell death by different mechanisms.  TcdA induces an apoptotic cell death while TcdB 
induces necrosis at concentrations ≥100 pM.  At low concentrations (≤10 pM), TcdB 
also induces an apoptotic cell death.  A cartoon model incorporating these data into a 
new intoxication model is shown in Figure 3.5. 
 
Discussion 
 
In order to fully elucidate the mechanisms toxins A and B utilize to drive disease 
pathology in vivo, it was important to design a study that allowed for the analysis of 
comparable doses of toxins at identical time points in the same tissue or cell type.  The 
ability to directly compare the two toxins and catalytic mutants allowed a unique 
resolving power in terms of understanding the different cellular processes engaged by  
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Figure 3.4.  TcdA induces glucosyltransferase-dependent caspase-3 activation, while TcdB 
induces glucosyltransferase-independent ROS production in colonic tissue.  A, Colonic 
explants were treated with 10 nM TcdA, TcdA D285/287N, TcdB, or TcdB D286/288N in 
incubated at 37 °C for 5 hours.  Tissue sections were stained with H&E.  B, Colonic explants were 
treated with ROS detection agent and incubated at 37 °C for 1 hour.  Samples were then treated 
with toxin at 37 °C for 5 hours after which the tissue was flash frozen.  Slides were prepared and 
immediately imaged.  C, Tissue sections were stained with an active caspase-3 antibody (red).  
Fluorescent and bright field images in B and C were captured using confocal microscopy. 
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each toxin, the dose at which the toxin was capable of injuring the cell or tissue, and the 
relative contribution of the glucosyltransferase activity of the toxins.  Initially, we sought  
to establish the physiologically relevant concentrations of toxin by challenging colonic 
explants with a range of toxin concentrations.  This dosing of the toxins led to two 
surprising observations.  First, both toxins were capable of inducing damage at 
concentrations above 10 pM (Figure 3.1).  This observation is consistent with the effects 
of TcdA intoxication in animal model systems such as hamsters, mice, rats, and rabbits 
[67-69,132,133]; although it was surprising given the difficulty of detecting TcdA induced 
death in tissue culture models [9,20,105,115,174].  Also of note, was the fact that the 
overall damage scores were highly similar. Taken together, these data suggest that cell 
death is a physiologically relevant consequence of TcdA intoxication and an important 
pathway to understand.   
This observation led us to seek out a cell line where both toxins could be 
assayed for cytotoxicity, and delineate these as apoptotic or necrotic death events.  
TcdA has historically been described as an enterotoxin while TcdB has been known to 
be a potent cytotoxin, implying an intrinsic difference in cytotoxic potency[123,129].  
YAMC cells, a conditionally immortalized cell line, are sensitive to TcdA as well as TcdB 
(Figure 3.2).  Using YAMC cells, we could readily detect TcdA induced cell death at a 
wide range of concentrations (100 nM to 10 fM) in 18 hours (Figure 3.2).   TcdB induced 
cell death was also readily detectable down to 10 fM at the same time point.  In both the 
colonic explant and the YAMC experiments at the non-permissive temperature (37 °C), 
p53 is unperturbed and toxins cause similar damage (Figure 3.1 and 3.2B). Notably, 
TcdB does not require p53 function at concentrations ≥ 100 pM (Figure 3.2A).  These 
data highlight the importance of working in model systems with intact apoptotic 
pathways when studying the death mechanism of TcdA, and sub-picomolar 
concentrations of TcdB (Figure 3.2).  The observation that TcdB induces a p53-
independent death at higher concentrations and a p53-dependent death at lower 
concentrations could readily explain the disparity in cell death events reported by many 
different groups over the years (Figure 3.2).  Studies where TcdB is used at high 
picomolar to nanomolar concentrations report necrosis [100,174,175], while sub-
63 
 
picomolar intoxication results in an apoptotic event consistent with the p53 dependence 
profile observed in YAMC cells [21,126,142,150,151].   
  
 
 
 
 
 
 
 
 
 
 
While TcdA and TcdB have been shown to have different effects on tissue and in 
animal models, they were thought to induce the same apoptotic cell death mechanism 
[9,20,21,126,142-145,150,151].  We have previously shown that TcdB induces a 
glucosyltransferase-independent necrotic cell death as a result of aberrant ROS 
production through the NADPH oxidase complex [174,175].  To further investigate the 
possibility that TcdB is inducing a concentration dependent mechanism that switches 
Figure 3.5.  TcdA and TcdB intoxicate cells by distinct mechanisms.  TcdA and low 
concentrations of TcdB intoxicate cells by ligating the host cell receptor, initiating endocytosis.  As the 
endosome matures, the low pH induces a conformational change that allows endosomal membrane 
disruption and translocation of the APD and GTD to the cytosol.  Upon encountering the cytosol, InsP6 
binds the APD and allosterically activates the enzyme and induces cleavage.  The GTD is then 
released into cell where it is trafficked to it target, membrane-bound Rho family GTPases.  
Glucosylation of GTPases leads to CPE and apoptosis.  Higher concentrations of TcdB initiate the 
assembly and activation of the NOX complex leading to necrosis.  Ligation of the host cell receptor 
initiates endocytosis and the recruitment of the cytosolic components of the NOX complex (activated 
Rac1, NOXO, and NOXA) to the membrane bound components (NADPH oxidase and p22).  As the 
endosome matures, the NOX complex is activated producing and releasing large amounts of ROS into 
the cytosol.  The aberrant production of ROS quickly leads to loss of membrane integrity and a 
necrotic cell death. 
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from necrosis to apoptosis, we used indicators of necrosis or apoptosis to determine the 
death pathway activated at a given concentration.  Here, we can clearly see in YAMC 
cells that TcdA induces an apoptotic cell death at all concentrations.  Additionally, the 
induction of apoptosis by TcdA is completely dependent on a fully active 
glucosyltransferase.  Most interestingly, we can observe two distinct cell death 
mechanisms occurring in response to TcdB.  At higher concentrations (≥100 pM), we 
see clear indications of a necrotic cell death including ROS production, rapid LDH 
release, and minimal caspase activation.  At lower concentrations (≤10 pM) where there 
are no indicators of necrosis, we see a rise in caspase activation indicating an apoptotic 
cell death.  Also clearly demonstrated in Figure 3.3D, the activation of the apoptotic 
pathway at lower concentrations of TcdB mirrors TcdA in that it requires 
glucosyltransferase activity.  This is the first report of TcdB inducing a bimodal cell 
death mechanism, dependent upon concentration of toxin, allowing the unification of the 
observations described by groups with seemingly opposing data (Figure 3.5).   
 We were able to extrapolate and confirm our findings in the colonic explant 
model.  At a concentration of 10 nM toxin, TcdA induces a glucosyltransferase 
dependent apoptotic cell death while TcdB induces the glucosyltransferase independent 
production of ROS (Figure 3.4).  We have demonstrated that a concentration of 10 nM 
TcdA and TcdB can induce a pathological response in tissue while intoxication with 10 
pM toxin has minimal effect (Figure 3.1).  We recognize that a 5 hour time point is not 
representative of the entire course of infection, and perhaps is more reflective of severe 
disease.  Our current explant model system does not allow for longer time points, which 
may be useful for understanding the effects of lower concentrations of toxin.  While it 
remains unclear how much toxin is present at the site of infection, we would 
hypothesize that both cell death mechanisms can be induced during the course of 
disease.  It is also reasonable to hypothesize that both mechanisms of cell death should 
be targeted to effectively combat disease in a toxin-centric therapeutic strategy.  The 
relative contribution of each toxin, and the respective mechanism of cell death induced, 
to overall pathology and disease represents an important question demanding future 
investigation.   
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CHAPTER IV 
 
 
ZINC IS A REGULATOR OF CLOSTRIDIUM DIFFICILE TOXIN ENZYMATIC 
ACTIVITY 
 
 
Introduction 
 
 
 Clostridium difficile is the leading cause of hospital-acquired diarrhea and 
secretes two large toxins, TcdA and TcdB [15,63,64,162].  Clostridium difficile infection 
(CDI) is a toxin-mediated disease that encompasses a wide range of disease symptoms 
from mild diarrhea to pseudomembranous colitis [29,161,181].  TcdA and TcdB are 
composed of four functional domains: receptor binding, delivery, an autoprocessing 
domain (APD) and a glucosyltransferase domain (GTD) [102,109,110,163]. The C-
terminal combined repetitive oligopeptide (CROPS) region of the toxin is thought to be 
involved in host cell receptor binding [8].  The delivery domain is a large hydrophobic 
region thought to undergo a significant conformational change in the low pH of the 
endosome that allows for disruption of the endosomal membrane and translocation of 
the APD and GTD into the cytosol of the host cell [95,99].  The autoprocessing domain 
has been thought to engage in cysteine protease activity, cleaving the GTD upon 
binding of host-cell inositol hexakisphosphate (InsP6) [102].  Once released, the GTD 
has been shown to target Rho family GTPases [108].  Glucosylation of these small 
GTPases leads to both cytoskeletal rearrangements in which the cells round, known as 
the cytopathic effect (CPE), and an apoptotic cell death [9,142].   
The autoprocessing activitiy is thought to be important for TcdA-induced cell 
death and the apoptotic cell death induced by lower concentrations of TcdB 
[32,103,104,174].  The domain is an attractive drug target because it contains a defined 
catalytic active site and an InsP6 binding pocket [4].  It is conceivable that either 
inhibition of autoprocessing or early activation of autoprocessing could provide 
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therapeutic benefit, making a detailed understanding of the allosteric and enzymatic 
mechanism of auotoprocessing is a priority.    Here, we report new mechanistic insights 
into the regulation and function of TcdA and TcdB.   
 Transition metals are known to be essential cofactors in many cellular processes 
and the structure and function of proteins [182,183].  Metals are also known to be 
essential to the function of a number of bacterial effector proteins that cause disease 
[184-187].  In particular, the regulation and function of toxins secreted by at least two 
Clostridial species, botulinum neurotoxin (BoNT) and tetanus toxin (TeNT), is 
completely dependent upon zinc [188-190].  In this study, we describe the regulatory 
functions of zinc in the autoprocessing activity of TcdA and TcdB.  These insights 
advance our understanding of the mechanism by which the toxins initiate and carry out 
autoprocessing of the GTD and may help guide drug development efforts. 
  
 
Methods 
 
Plasmid Construction and Point Mutants 
Previously described plasmids for the recombinant expression of TcdA [2], 
TcdA1-1832, and TcdB were used as templates for all mutant proteins generated for this 
study. Mutations were introduced by site-directed mutagenesis using the QuickChange 
protocol.  
 
Protein Expression and Purification 
 Proteins were expressed and purified as previously described [191]. 
 
Cleavage assays 
 Cleavage assays were performed as previously described [191].  DTT, TCEP, 
and EDTA were added at the same time as InsP6.  Protein was preincubated with 
TPEN at 37 °C for 2 hours before the addition of InsP6.  Reactions were then incubated 
at 37 °C for an additional 2 hours. 
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Crystallization 
 TcdA1-1832 and S1329C TcdA1-1832 were concentrated to 10 mg/ml in 20 mM Tris, 
pH 8.0, 100 mM NaCl.  Crystallization was performed using the hanging drop method at 
21o C with a 1:1 ratio of protein to mother liquor. The mother liquor formulation for WT 
crystals was 100 mM Bis-Tris, pH 6, 11% PEG 4000, 30-50 mM guanidium chloride 
(GuCl).  The mother liquor formulation for the S1329C crystals was 100 mM Bis-Tris, pH 
5.8, 8% PEG 4000, 50 mM GuCl.  Crystals were exchanged into appropriate mother 
liquor containing 20% glycerol, mounted on cryo loops, and flash cooled in liquid 
nitrogen. 
 Heavy atom derivatives of TcdA1831 were prepared by soaking crystals in the 
appropriate mother liquor containing either 1 mM gold(III) chloride hydrate for 40 min or 
5 mM mercuric chloride for 1.5 h.  Heavy atom derivatives of S1329C TcdA1831 were 
prepared by soaking crystals in 5 mM mercuric chloride for 72 hours. 
 
Structure Determination and Refinement 
 X-ray data were collected from single crystals on LS-CAT beamline 21 ID-D at 
the Advanced Photon Source (Argonne, IL) at 100o K. Diffraction data were indexed, 
integrated, and scaled using XDS [192] or HKL2000 [193](Table 1).  The two mercury 
datasets were compared to the native dataset using multiple isomorphous replacement 
with anomalous scattering in SHARP [194].  The analysis revealed five mercury sites in 
the two mercury datasets, differing only in their occupancies, and was consistent with 
the expectation that each protein monomer would have five free cysteine residues.  The 
heavy atom positions were used to calculate initial phases, which were included in an 
auto-building protocol in PHENIX [195].  The fragments generated by auto-building 
guided manual placement of the apo-GTD structure (PDB ID 3SS1) [2].  Phases from 
the GTD model were combined with the phases from SHARP to calculate a new map 
and initiate a new round of autobuilding.  The fragments generated through autobuilding 
allowed for manual placement of the CPD (PDB ID 3H06) [4].  Phases from the 
combined GTD and CPD model were combined with the phases from SHARP to 
calculate a new map and initiate new rounds of automated and manual building.  
Further phase improvement came from multi-crystal averaging.  The working model 
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(consisting of the GTD, most of the CPD, and a series of unconnected fragments from 
the delivery domain) was used as search model for molecular replacement into the 
native, platinum, and gold datasets.  The models and phases from each dataset were 
subjected to multi crystal averaging and density modification in PHENIX and resulted in 
excellent quality maps.  One area of ambiguity was resolved through site specific 
introduction of a Hg atom: crystals of a S1329C TcdA1-1832 mutant were derivitized 
with mercuric chloride, and the sixth heavy atom site was identified using PHENIX. The 
model was generated through an iterative process of manual building in Coot [196] and 
refinement using Phenix [195].  The final model reflects the 50-3.25 Å native dataset 
(Rcryst = 22% , Rfree= 26%) and contains residues 4-944 and 951-1806 along with 1 zinc 
atom.  
 
X-ray absorption spectroscopy 
X-ray absorption spectroscopy (XAS) experiments were carried at beamline X3B of the 
National Synchrotron Light Source, which was equipped with a sagitally focusing 
Si(111) double crystal monochromator and a Ni-coated mirror for harmonic rejection. A 
He Displex cryostat was used for temperature control (~15K typical sample 
temperatures). Fluorescence detection was provided by a 31-element solid-state 
germanium detector array (Canberra). Samples of TcdA1-1832 (10 mg/mL) and buffer 
blanks were loaded into 30 µL polycarbonate cuvettes wrapped in 1 mil Kapton tape 
and then frozen by immediate immersion in liquid nitrogen. The Kɑ fluorescence 
emission spectra from TcdA1831 and buffer samples in the X-ray beam (incident energy 
= 10 keV) were examined. There was a significant increase in the total Zn fluorescence 
counts for the TcdA1831 sample compared to buffer, while fluorescence for the Mn - Cu 
series was unchanged. XAS measurements were therefore carried out at the Zn K-edge 
on TcdA1831, over an energy range of 9.46 – 10.3 keV. Internal energy calibration was 
provided by simultaneous measurement of a Zn metal foil, with the first inflection point 
of the edge set to a reference energy of 9659 eV. Calibration and averaging of XAS 
data was carried out using Athena [197]. 
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ICP-MS 
Proteins were prepared as described above and dialyzed overnight into metal free 
buffer conditions as indicated.  All buffers contained 50 mM NaCl; InsP6 was at a 
concentration of 10 mM, TPEN was at a concentration of 1 mM, ZnCl2 was at a 
concentration of 10 μM.  ZnCl2 buffers also contained 1 mM TCEP.  Samples dialyzed in 
TPEN and ZnCl2 buffers were dialyzed at room temperature for 8 hours.  All other 
samples were dialyzed at 4 °C for 18 hours.  Protein samples were analyzed for metal 
content by utilizing 50 µL of the protein solution and diluting in 2.5% (v/v) nitric acid 
(Sigma-Aldrich, TraceSELECT quality) to a final volume of 3 mL for ICP-MS analysis.  
In samples with significant precipitation after acidification, the samples were centrifuged 
at 15,000 x g for 20 minutes to pellet any precipitate, and the solution transferred to a 
fresh tube for measurement.  The diluted samples were analyzed for 66Zn, 55Mn, 63Cu, 
and 60Ni using a 1 – 30 ppb standard curve utilizing stock solutions (Perkin Elmer).  
Analyses were performed using a PerkinElmer ELAN DRCII ICP-MS.  The instrument 
was equipped with a Microflow PFA-ST concentric nebulizer with a 100 μL/min self-
aspiration capillary, a cyclonic spray chamber, a quartz torch and nickel 
sampler/skimmer cones.  Germanium at 50 ppb was added as an internal standard 
using an EzyFit glass mixing chamber.  Concentrations (in ppb) were corrected for the 
dilution factor and the molar concentrations and molar ratios (66Zn/protein) were 
determined for each sample. 
 
 
Results 
 
TcdA autoprocessing is inhibited by a metal ion 
 We and others have observed the autoprocessing activity of TcdA is dependent 
upon the presence of a reducing agent (Figure 4.1A), as autocleavage of the GTD is not 
observed in reactions with InsP6 only.  With the addition of 100 mM dithiothreitol (DTT), 
TcdA autoprocesses in an InsP6-dependent manner, as previously reported [104].  
Curiously, TcdB holotoxin readily autoprocesses in the absence of reducing agent, 
indicating that the inhibitory mechanism present in TcdA is absent in TcdB (Figure 
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4.1A).  In addition to reducing disulfide bonds, DTT can also coordinate metals.  To 
begin to understand which chemical property of DTT was driving the induction of 
autoprocessing in TcdA, we tested other common chemical reagents with a similar 
chemical property to DTT.  Tris(2-carboxyethyl)phosphine (TCEP) is another commonly 
used reducing agent of the phosphine family and does not coordinate metals.  
Ethylenediaminetetraacetic acid (EDTA) is an efficient metal chelator, but has no effect 
on disulfide bonds.  We compared both of these reagents to the efficiency of DTT in the 
induction of an InsP6 dependent cleavage event.  TCEP did not induce autocleavage of 
TcdA, whereas addition of EDTA to the reaction did result in autoprocessing (Figure 
4.1B).  These data indicate that the metal chelating properties of DTT and EDTA 
promote autoprocessing, suggesting a metal ion must be removed from TcdA before 
autoprocessing can occur. 
 
 
 
TcdA coordinates three zinc ions in different functional domains 
 We next sought to identify the metal that was inhibiting autoprocessing of TcdA.  
We identified the metal in an X-ray absorption near edge structure (XANES) experiment 
with TcdA, where we observed a strong signal at the zinc edge (Figure 4.2A).  The 
spectrum collected was consistent with zinc coordination by both cysteine and histidine 
residues.  As a secondary and more quantitative method of identification, we also 
Figure 4.1.  TcdA requires reducing 
agent to initiate cleavage.  A, TcdB 
readily undergoes autoprocessing in an 
InsP6 dependent fashion.  TcdA, 
however, does not autoprocess without 
the addition of 100 mM DTT.  B, Initiation 
of autoprocessing was tested using 
different chemical additives, DTT, TCEP, 
and EDTA.  100 mM of the compound 
was added to the indicated reactions, and 
10 mM InsP6 was added to the indicated 
reactions.  All reactions were incubated at 
37 °C for 2 hours before the reactions 
were stop with the addition of Laemmli 
buffer.  The samples were analyzed by 
Coomassie stained SDS-PAGE 
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assessed the occupancy of TcdA using inductively coupled plasma mass spectrometry 
(ICP-MS).  In this experiment, we again identified zinc as the metal coordinated by the 
toxin.  Surprisingly, we calculated a zinc:toxin molar ratio of 3.36 (Table 4.1, black).  
Tetanus toxin (TeNT), known to bind one zinc ion, was analyzed as a control in ICP-MS 
experiments.  To determine where in the toxin the zincs were coordinated, we made a 
series of C-terminal truncations and determined the molar ratio of zinc:toxin.  The molar 
ratio of zinc to protein for a toxin where the CROPS domain was deleted (TcdA1-1832) 
was 1.93 (Table 4.1, black).  The loss of one zinc with the deletion of the CROPS 
suggests that one zinc is either coordinated in the deleted domain or within the interface 
between the CROPS and another domain.  The zinc coordinated by the CROPS is not 
the zinc that inhibits autoprocessing activity, however, as EDTA is still required to 
induce cleavage (Figure 4.2B).  Further deletion of the delivery domain (TcdA1-809) 
revealed a zinc:toxin ratio of 0.52 by ICP-MS (Table 4.1, black).  The loss of a zinc ion 
suggests the second zinc is coordinated within the delivery domain, leaving the third 
zinc coordinated somewhere in the APD or GTD.  Importantly, the zinc coordinated by 
the delivery domain is the metal ion that inhibits autoprocessing activity.  Loss of this 
zinc resulted in the loss of requirement for EDTA to induce cleavage (Figure 4.2B), 
indicating the inhibitory zinc is coordinated by residues either within the delivery domain 
or at an interface between the delivery domain and another domain. 
 To further define the binding site of the inhibitory zinc, we made two additional C-
terminal deletion mutants in the delivery domain: TcdA1-1809 and TcdA1-1795.  When we 
tested these truncation mutants for their dependence on EDTA for autoprocessing 
activity, we found that the TcdA1-1809 protein still required EDTA which indicated that the 
inhibitory zinc was still coordinated (Figure 4.2C).  The TcdA1-1795 protein did not require 
the addition of EDTA to initiate cleavage, indicating the inhibitory zinc was no longer 
coordinated (Figure 4.2C).  These data suggest the coordinating residues for the zinc 
ion that inhibits autoprocessing activity are located between residues 1795 and 1809.  
There are four potential metal coordinating residues within this 14 amino acid stretch: 
E1803, E1805, D1807, and D1809.  Importantly, three of the four (E1805, D1807, and 
D1809) are not conserved between TcdA and TcdB (Figure 4.2D).  We would expect  
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Figure 4.2.  TcdA autoprocessing 
activity is inhibited by a zinc ion 
coordinated at the interface of the 
delivery domain and APD.  A, 
XANES spectra of TcdA in solution. 
The shape of the X-ray absorption 
near-edge spectrum (XANES) 
supports a zinc site with mixed 
nitrogen/sulfur ligation.  B, Cleavage 
assays with TcdA, TcdA1-1832, and 
TcdA1-809.  C, Cleavage assays with 
the addition of TcdA1-1809 and TcdA1-
1795.  All reactions contained 10 mM 
InsP6.  Indicated reactions contained 
100 mM EDTA.  Reactions were 
incubated at 37 °C for 2 hours.  D, 
Sequence alignment of TcdA 1795-
1809 and TcdB 1798-1812 with 
Expasy LALIGN.  E, Crystal structure 
of TcdA1-1832 focused on the 
putative zinc coordination site.  
Putative coordinating residues, E572, 
E573, E646, E1805, E1807, and 
E1809 are highlighted. 
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Sample Zinc/Protein Buffer 
TcdA 3.36 20 mM HEPES pH 6.9 
TcdA1-1832 1.93 20 mM HEPES pH 6.9 
TcdA1-1832 0.72 100 mM BisTris pH 6.0 
TcdA1-809 0.52 20 mM HEPES pH 6.9 
TeNT 0.75 20 mM HEPES pH 6.9 
  
 
  
TcdA1-1795 0.79 20 mM HEPES pH 6.9 
C700A 0.08 20 mM HEPES pH 6.9 
H655A 0.06 20 mM HEPES pH 6.9 
H759A 0.3 20 mM HEPES pH 6.9 
L542A 0.77 20 mM HEPES pH 6.9 
TcdA1-1795 + InsP6 0.54 20 mM HEPES pH 6.9 
L542A + InsP6 0.45 20 mM HEPES pH 6.9 
TcdA1-1795 + TPEN 0.04 20 mM HEPES pH 6.9 
TcdA1-1795 + ZnCl2 0.48 20 mM HEPES pH 6.9 
  
 
  
TcdB 0.67 20 mM HEPES pH 6.9 
C698A 0.09 20 mM HEPES pH 6.9 
H653A 0.04 20 mM HEPES pH 6.9 
H757A 0.31 20 mM HEPES pH 6.9 
L543A 0.67 20 mM HEPES pH 6.9 
TcdB + InsP6 0.5 20 mM HEPES pH 6.9 
L543A + InsP6 0.47 20 mM HEPES pH 6.9 
TcdB + TPEN 0.05 20 mM HEPES pH 6.9 
TcdB + ZnCl2 0.38 20 mM HEPES pH 6.9 
 
 
 
 
 
 
Table 4.1.  ICP-MS determination of zinc 
occupancy in Clostridium difficile toxins. 
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the zinc coordinating residues to not be conserved in TcdB as there is no inhibitory zinc 
ion by both ICP-MS and cleavage assays.  
 Stacey Seeback crystallized the TcdA1-1832 protein.  The residues involved in the 
putative coordination site for the inhibitory zinc are localized to the base of the globular 
head domain at the interface of the delivery domain and the APD (Figure 4.2E).  It is 
reasonable to hypothesize that residues in the APD could also be involved in the 
inhibitory zinc coordination site.  Potential coordinating residues located at the interface 
include Glu572, Glu573, Glu646, and Glu694.  Also of note, the InsP6 binding site is 
located ‘behind’ the putative coordination site (Figure 4.2E).  Occluding the allosteric 
binding site of the enzyme may be one mechanism of regulation employed by the 
inhibitory zinc. 
 
Low pH releases the inhibitory zinc 
 We wondered how this inhibitory zinc would be released in the context of cellular 
intoxication and hypothesized it may occur when the toxin encounters the low pH of the 
endosome.  To test this, we performed a pH titration resembling the maturation cycle of 
an endosome and assessed the ability of the toxin to undergo autoprocessing with the 
addition of InsP6.  As seen in Figure 4.3A, autoprocessing does not occur at neutral pH 
which the toxin may encounter on the cell surface.  Cleavage begins at a pH of 6.0 and 
increases at pH 5.5, suggesting that low pH does release the inhibitory zinc and allow 
autoprocessing to occur.  These pHs resemble that of an early endosome.  
Autoprocessing continues to occur down to pH 4.5, the pH of the lysosome (Figure 
4.3A). 
 Interestingly, when we docked the TcdA1-1832 structure into the EM structure, at 
both neutral and low pH [5], we noticed that the point of rotation for the large 
conformational change appears to be near the putative inhibitory zinc binding site 
(Figure 4.3B).  Together, these data demonstrate that pH dependent release of the zinc 
and conformational change may be another mechanism by which zinc regulates 
autoprocessing activity.  
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A second zinc is coordinated in the autoprocessing active site 
 We were able to collect zinc anomalous data with the TcdA1-1832 crystals, in which 
we detected one zinc.  Unexpectedly, the zinc, colored in green, was coordinated in the 
catalytic active site of the APD, colored in blue (Figure 4.4A).  The protein was 
crystallized in the absence of InsP6, unlike other structures of the APD alone, revealing 
a new active site conformation.  In the TcdA1-1832 active site, in addition to the known 
catalytic residues Cys700 and His655, we see His759 also coordinating the zinc (Figure 
4.4B).  The structure of TcdA1-1832 was determined at a moderate resolution of 3.25 Å, 
preventing the visualization of water molecules.  Though we cannot see a water 
molecule, there is space for a water to be hydrogen bonded to Glu544/Asp545 and 
complete a tetrahedral coordination of the active site zinc (Figure 4.4B). 
To confirm the presence of the zinc in the active site was not an artifact of 
crystallization, we analyzed the point mutants C700A, H655A, and H759A for the 
presence of zinc by ICP-MS (Table 4.1, blue).  ICP-MS experiments investigating the 
active site zinc were performed using the TcdA1-1795 protein, which does not coordinate 
Figure 4.3.  The inhibitory zinc is released upon exposure to low pH.  A, Cleavage 
assays in 20 mM MES buffer at pHs 4.5 to 7.0.  Indicated reactions contained 10 mM 
InsP6.  The pHs tested resemble that of the pH of a maturing endosome.  The TcdA1-
1832 structure was placed in the 20 Å EM structures of TcdA holotoxin at B, neutral 
(upper) and C, acidic (lower) pH.  The EM structures were calculated by single particle 
averaging and random conical tilt as previously described [5]. The crystal structure was 
fit in each map using Chimera [11]. 
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the inhibitory zinc, to simplify data and interpretation.  This analysis demonstrated that 
Cys700 and His655 are clearly zinc coordinating residues.  His759, however, is more 
ambiguous with a zinc:protein molar ratio of 0.3 (Table 4.1, blue).  It is possible that 
His759 is a coordinating residue, but in its absence another residue may donate 
electrons needed to complete coordination of the zinc resulting in the signal we detect 
by ICP-MS (Figure 4.4B).  We would hypothesize that the binding of this modified site is 
significantly less tight, resulting in the lower occupancy we detect by ICP-MS (Table 4.1, 
blue).  The presence of a zinc ion in the H759A mutant was confirmed upon the 
determination of a TcdA1-1832 H759A crystal structure at the zinc anomalous wavelength.   
 
 
 
  
 
Figure 4.4.  A zinc ion is 
coordinated in the APD 
active of TcdA and TcdB.  
A, A cartoon representation 
of the TcdA1-1832 crystal 
structure colored as in 
Figure 1.1.  The GTD is 
red, APD is blue, delivery 
domain is yellow, and a 
zinc atom is indicated in 
green.  B, Analysis of the 
anomalous zinc signal, 
reveals a single peak, 
shown here in purple at 7 
sigma, located in the APD 
active site.  The zinc is 
coordinated by H655 (2.7 
Å), C700 (2.7 Å), and H759 
(2.2 Å) and may have 
indirect contacts with E544 
or D545.  The blue mesh 
depicts a 2Fo-Fc map 
contoured around the 5 
active site amino acids at 1 
sigma.  C, Cleave assays 
in the crystallization buffer, 
100 mM BisTris pH 6.0, 50 
mM GuCl, used to obtain 
the structure of TcdA1-1832.  
Reactions contained 100 
mM EDTA and 10 mM 
InsP6 as indicated. 
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It is important to note that there is a zinc coordinated in the active site of TcdB, 
also.  We demonstrated this by analyzing the active site mutants, C698A, H653A, and 
H759A for zinc content.  The zinc:protein molar ratio of each sample was similar to the 
equivalent mutation in the TcdA truncation.  The Cys698 and His653 residues are 
clearly coordinating the active site zinc, as the zinc:protein molar ratio approached zero.  
Similar to TcdA, the His757 residue has an intermediate phenotype in which the molar 
ratio of zinc:protein is ~0.3 (Table 4.1, blue). 
 We were perplexed as to why we did not see a second zinc coordinated in the 
delivery domain by anomalous scattering, as was suggested by our previous ICP-MS 
data with the TcdA1-1832 protein.  The crystallization conditions included a BisTris pH 6.0 
buffer, which we hypothesized may release the inhibitory zinc.  If this were true, we 
would expect the toxin to autoprocess with the addition of InsP6 alone without the 
presence of EDTA.  We performed this experiment and found that the BisTris pH 6.0 
buffer was sufficient to remove the inhibitory zinc (Figure 4.4C), allowing autoprocessing 
to occur in the absence of chelator and preventing visualization by X-ray crystallography 
(Figure 4.4A).  The loss of this zinc was confirmed by ICP-MS (Table 4.1, black). 
  
His759 is an essential residue in allosteric regulation by InsP6 
 To begin to understand the function of the active site zinc, we first investigated 
the effect that mutating the His759/757 residue, previously unknown to be involved in 
catalysis, would have on autoprocessing activity.  When we assessed the cleavage 
activity of TcdA1-1795 H759A and TcdB H757A, we noticed that initiation of catalysis still 
required the presence of InsP6, but was no longer dependent upon InsP6 
concentration, suggesting that this residue is a key regulator of InsP6 allostery in both 
TcdA and TcdB, respectively (Figure 4.5A).  There is structural evidence for this 
hypothesis.  When we compare the structure of the APD from the TcdA1-1832 structure in 
the absence of InsP6 and the structure of the APD alone with InsP6 bound, we see an 
impressive 19 Å movement out of the active site (Figure 4.5B).  The residue sits at the 
base of the β-flap, previously described as the secondary structure communicating the 
allosteric regulation of InsP6-induced autoprocessing (Figure 4.5B).   
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The active site zinc is required for enzymatic function 
 An obvious question upon the discovery of a zinc in the catalytic active site is the 
function of the zinc in catalysis.  We could think of two reasonable possibilities.  The 
active site zinc could inhibit catalysis, as has been reported for caspase family 
members.  If this were true, we would expect zinc to no longer be coordinated by the 
toxin after InsP6 binding.  To test this, we dialyzed TcdA1-1795 and TcdB in the presence 
of InsP6 and analyzed these samples by ICP-MS.  We conducted a similar experiment 
Figure 4.5.  His759/757 is a key residue is the allosteric regulation TcdA and TcdB 
induced by InsP6.  A, Cleavage assays comparing autoprocessing activity of wild type 
TcdA1-1795 and TcdB to their respective mutants, H759A and H757A.  B, The APD and 
three-helix bundle from the TcdA1-1832 structure  is depicted on the left with residues 
543-745 in white, the 746-765 β-flap in light blue, and the three helix bundle (766-841) 
in dark blue and yellow.  A zinc atom (green) is bound in the CPD active site by H655, 
C700, and H759.  Four lysines form the initial binding site for InsP6: K602, K649, K754, 
and K777.  Comparison to the InsP6-bound structure of the TcdA APD  (right) suggests 
significant structural changes occur with InsP6 binding: the accumulation of 8 lysines 
and 1 arginine in the InsP6-binding site, a rearrangement of the β-flap and elements of 
the three-helix bundle, and displacement of H759 from the active site. 
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with the cleavage site mutants L542A and L543A, in TcdA1-1795 and TcdB, respectively.  
These mutants should bind InsP6, but not cleave.  We found that zinc was present in 
every sample, indicating that the zinc ion is not displaced upon InsP6 binding (Table 
4.1, red).  Alternatively, the zinc could be required for catalysis acting as an activator of 
a water molecule as in a metalloprotease.  We used N,N,N',N'-tetrakis(2-
pyridylmethyl)ethane-1,2-diamine (TPEN), a chelator specific for zinc, to test this 
hypothesis.  We pretreated both TcdA1-1795 and TcdB with TPEN for 2 hours at 37 °C, 
and then incubated the toxin with InsP6 for an additional 2 hours at 37 °C.  We found 
that pretreatment of the toxin with TPEN resulted in a loss of zinc and a loss of 
autoprocessing activity, suggesting that the zinc is required for catalytic activity (Figure 
4.6A).  Importantly, we also pretreated TcdA1-1795 H759A and TcdB H757A with TPEN to 
test whether we would see the same effect as in wild type TcdA and TcdB.  We again 
observed a loss in all autoprocessing activity of the mutants, further suggesting zinc-
dependent enzymatic activity (Figure 4.6B).  To confirm we were extracting the zinc 
from the active site, we analyzed samples dialyzed with TPEN for their zinc content 
using ICP-MS (Table 4.1, red).  In samples devoid of zinc, we observed a deficient 
autoprocessing (Figure 6C).  We were also able to restore zinc binding, again confirmed 
with ICP-MS (Table 4.1, red), and restore activity (Figure 4.6C), further supporting the 
observation that C. difficile toxins require zinc for their autoprocessing activity. 
 
Discussion 
 
 The autoprocessing activity of C. difficile toxins has been the subject of many 
investigations in the past.  The enzymatic activity has been thought to be required for 
toxin-induced cell death, and has therefore been considered a viable drug target [3,102-
104].  There is at least one report describing the observation that commonly used 
reducing agents, DTT and β-mercaptoethanol (BME), initiate autocatalytic activity in 
TcdA [104].  Another earlier study reported EDTA did not inhibit cleavage.  DTT, BME, 
and EDTA have also all been described as metal chelators [198-200].  Here we 
demonstrated that DTT and EDTA can activate TcdA and allow autoprocessing to 
occur, whereas TCEP, another commonly used reducing agent that cannot chelate 
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metals, does not promote autoprocessing (Figure 4.1).  This observation led us to 
determine the identity of the metal ion that was inhibiting autoprocessing.  Using two 
independent methods of identification, XANES and ICP-MS, we discovered that TcdA 
coordinates at least 3 zinc ions (Figure 4.2A, Table 4.1). 
 
 
 
 We localized at least one coordinating residue of the inhibitory zinc to the 14 
amino acids between 1795 and 1809 using a series of truncation mutants analyzed by 
both ICP-MS and autoprocessing activity (Figure 4.2C, Table 4.1).  There are four 
potential zinc coordinating residues within these 14 amino acids including two Glu 
residues and two Asp residues.  Intriguingly, three of these residues are not conserved 
in TcdB.  We might expect the residue(s) coordinating the zinc to be absent in TcdB, as 
Figure 4.6.  TcdA and TcdB are 
zinc-dependent proteases.  
Cleavage assays investigating the 
autoprocessing activity of A, TcdA1-1795 
and TcdB and B, TcdA1-1795 H759A 
and TcdB in the presence of 10 mM 
TPEN.  Reactions in the absence of 
TPEN were run in a control buffer 
containing 2.5% ethanol.  C, Cleavage 
assays with samples analyzed by ICP-
MS (Table 4.1).  The reactions were 
run in each sample’s dialyzate.  
Indicated reactions contained 100 μM 
InsP6 pretreated with 100 mM TPEN.  
Reactions were incubated at 37 °C for 
2 hours and analyzed by Coomassie 
stained SDS-PAGE. 
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there is no inhibitory zinc binding at this site in the delivery domain (Figure 4.2D).  
Unfortunately, single point mutation of these four residues in TcdA has not abrogated 
the requirement for EDTA in autoprocessing.  It may be that two or more mutations will 
be needed to eliminate zinc binding at this location.  It is important to note that neither 
the inhibitory zinc nor its putative coordinating residues were visible in the crystal 
structure recently determined by our lab.  The buffer conditions were shown to release 
the inhibitory zinc and allow autoprocessing.  Taking note of the location of the last 
visible residue in the structure (1802), however, the next several residues, of interest, 
would likely reside at the interface of the delivery domain and APD (Figure 4.2E).  It is, 
therefore, possible that residues on the APD side of the interface are also coordinating 
the inhibitory zinc.  Using the positions of residues in the TcdA1-1832 structure, we have 
mutated several residues in the APD potentially coordinating the zinc: Glu572, Glu573, 
Glu646, and Glu694 (Figure 4.2E).  These mutants have not yet been tested by ICP-MS 
or cleavage assay to determine whether the residues are important for zinc 
coordination.   
 We hypothesize that the presence of the inhibitory zinc in TcdA and absence in 
TcdB has a functional consequence in the cellular intoxication mechanism.  It is 
possible that the regulatory mechanism implemented by the inhibitory zinc is to ensure 
that autoprocessing occurs in the proper environment.  We and others have shown that 
TcdA induces a GT-dependent apoptotic cell death, making pH dependent translocation 
of the GTD important for the intoxication mechanism of TcdA.  We have shown that the 
zinc can be released upon exposure of TcdA to a pH of 6.0 or lower, resembling that of 
a maturing endosome (Figure 4.3).  Perhaps the regulatory function of the inhibitory zinc 
is to allow cleavage of TcdA only upon progression into the late endosome to ensure 
proper translocation, cleavage, and trafficking of the GTD to its target GTPase.  The 
putative binding site of the inhibitory zinc is positioned at the interface of the delivery 
domain and the APD (Figure 4.2E).  Notably, this may also be the point of rotation for 
the conformational change induced by low pH observed by EM (Figure 4.3B) [5].  This 
observation provides structural support for hypothesis that the inhibitory zinc is 
important for the spatial regulation of TcdA autoprocessing activity.  
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The TcdA and TcdB APD were defined as a cysteine protease first by homology 
to the MARTx toxin from Vibrio cholerae (VcRTx) [104].  Subsequent mutagenesis of 
the homologous catalytic residues, Cys700, His655, and Asp589 in TcdA, resulted in 
deficient autoprocessing activity [4,32,104,158].  Chemical modification of the presumed 
catalytic cysteine with N-ethylmaleimide (NEM), iodoacetate, and novel substrate 
mimetics provided further evidence of cysteine protease activity [3,104].  In each case, 
the mutation or covalent modification of the catalytic cysteine would result in abrogation 
of zinc coordination, as demonstrated by the ICP-MS data with C700A (Table 4.1), 
which would result in loss of enzymatic activity.  A more recent study describing the 
detectable nitrosylation of Cys700 also describes the modified toxin as deficient in 
catalytic activity [32].  Similarly, nitrosylation is a covalent modification that would 
interfere with zinc coordination [201].  Notably, the Asp589 is not in the catalytic active 
site in the TcdA1-1832 structure (Figure 4.4B).  It appears, instead, to act as a hydrogen 
bonding partner with His655, perhaps explaining the diminished but not abrogated 
autoprocessing activity observed upon its mutagenesis.   
 The crystal structure of TcdA1-1832 revealed an unknown residue in the APD 
active site (Figure 4.4A and 4.4B).  His759 contributes to the coordination of zinc, 
though its binding affinity appears to be significantly lower than the other residues in the 
active site, Cys700 and His655, based on ICP-MS data (Table 4.1).  Mutating His759 
results in autoprocessing activity that is independent of InsP6 concentration, 
demonstrating that this residue is important in the allosteric regulation of InsP6 binding 
(Figure 4.5A).  This finding lends support to the reports that InsP6 binding is 
communicated through the β-flap, as His759 is positioned at the base of flap.  In 
comparing the structure of TcdA1-1832 in the absence of InsP6 and the TcdA APD alone 
bound to InsP6, we observe a large 19 Å displacement of InsP6 out of the active site 
(Figure 4.5B).   
 Our experiments with TPEN, a zinc specific chelator, suggest that TcdA and 
TcdB are zinc-dependent proteases (Figure 4.6).  The dependence upon zinc is not new 
to Clostridial toxins, as both botulinum neurotoxin and tetanus toxin are known zinc 
proteases [188-190].  The catalytic active site of C. difficile toxins is unusual, however.  
Enzymatic coordination sites typically do not contain cysteine residues, though there are 
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examples such as alcohol dehydrogenase [201].  It is important to note that the 
conformation of the active site in the TcdA1-1832 structure is likely not the conformation in 
which catalysis occurs.  We have evidence that His759 moves out of the active site 
upon InsP6 binding (Figure 4.5), which is known to be required for autoprocessing to 
occur.  We hypothesize that His759 provides steric hindrance and prevents the 
substrate from binding before InsP6 binds.  Once His759 relocalizes, the substrate is 
then allowed to bind forming a new, unknown coordination site for the zinc.  Perhaps 
this required relocalization of His759 before the enzyme is fully active is similar to the 
“cysteine switch” mechanism of activation first described in collagenase [202].  The 
identities of the residues involved in the coordination of the zinc are presumed to 
include either Cys700 or His655.  Crystal structures of VcRTx and TcdB in the presence 
of InsP6 with the substrate or covalent inhibitor, respectively, bound indicate that the 
substrate lies in between Cys700 and His655 [1,3].  Our lab has also preliminarily 
determined the structure of the TcdA APD in the presence of InsP6 in which the 
substrate is bound, revealing a similar confirmation.  Unfortunately, in each study, 
Cys700 was either mutated or covalently modified, resulting in loss of zinc coordination.  
Ideally, we could determine the structure of a mutant that did not ablate zinc binding 
such as the cleavage site mutant, L542A.  Efforts to achieve this structure are ongoing, 
though thus far have been unsuccessful.  For now, we can speculate based on the 
available substrate bound structures.  There may be a possible coordination site on the 
Cys700 side of the substrate including Glu745 and Trp761.  Efforts to determine the 
involvement of these residues by site-directed mutagenesis are underway.   
 In this study, we have demonstrated an essential and novel regulatory function of 
zinc in the enzymatic activity of C. difficile toxins.  There are at least three zincs 
coordinated by TcdA, and we have described the functions of two here.  One zinc is 
inhibitory and must be released before autoprocessing can occur.  It is thought that this 
zinc is coordinated in the interface between the delivery domain and the APD.  This 
coordination site may prevent InsP6 binding before the toxin has reached the low pH of 
a mature endosome.  Another zinc is coordinated in the catalytic active site of the APD.  
This zinc has been shown to be required for catalytic activity and could activate a water 
molecule in a metalloprotease mechanism of action.  Many details of the coordination 
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sites and the catalytic mechanism of the active site zinc remain unanswered and are 
active areas of investigation. 
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CHAPTER V 
 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
Conclusions 
 
 When this project began, it was thought that TcdA and TcdB were homologous 
toxins that intoxicated cells by identical mechanisms and killed cells by inducing 
apoptosis.  Additionally, autoprocessing and glucosyltransferase activity were thought to 
be required for toxin function and toxicity.  As mediators of CDI, the toxins are viewed 
as drug targets where small molecule or biological inhibitors could provide novel 
treatment strategies for the disease.  We conducted a high throughput small molecule 
inhibitor screen to identify compounds that protected cells from TcdB-induced cell 
death.  In the process of this endeavor and the development of secondary assays, we 
discovered that TcdB induces a necrotic mechanism of cell death that is independent of 
both the autoprocessing and glucosyltransferase activities of the toxin (Chapter II).  Dr. 
Melissa Farrow and I have since discovered that the necrosis induced by TcdB is a 
result of aberrant, NADPH oxidase (NOX)-derived reactive oxygen species (ROS) 
production.  With a new understanding of the mechanism by which cells were dying, we 
returned to the confirmed hits identified from the small molecule inhibitor screen.  0449, 
one of the top hits from the screen, has been an invaluable tool in dissecting the NOX 
mechanism unique to TcdB.  Our data demonstrate that calcium is a key component of 
the TcdB-induced NOX production of ROS (Appendix I). 
 Using a conditionally immortalized cell line, YAMCs, we observed for the first 
time a clear bimodal cell death induced by TcdB.  At nanomolar concentrations, we 
observe GT-independent, NOX-driven necrosis, consistent with our observations in 
transformed cell lines.  At low picomolar concentrations and below, however, we 
observe GT-dependent apoptosis that is likely occurring through a p53-dependent 
pathway.  We were also able to directly compare the cell death mechanisms induced by 
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TcdA and TcdB side-by-side, in the same cell line and at the same time points.  In doing 
so, we demonstrated that TcdA is a potent cytotoxin, killing cells and damaging colonic 
tissue in a concentration range and time frame similar to that of TcdB.  This potency had 
not been observed in previous studies using transformed cell lines.  We also supported 
previous observations that TcdA induces a GT-dependent, p53-dependent apoptotic cell 
death.  Our mechanistic observations made in YAMC cells intoxicated with TcdA and 
TcdB were recapitulated in colonic tissue, providing evidence that the mechanisms of 
cell death observed in YAMC cells are relevant in pathogenesis.  This report allowed for 
the unification of the field’s differing observations (Chapter III). 
 We also discovered that TcdA autoprocessing activity is regulated by the 
coordination of at least two zinc ions (Chapter IV).  One zinc acts as an inhibitor of 
enzymatic activity and must be extracted before cleavage is observed.  This regulatory 
mechanism is not present in TcdB.  The binding site of this inhibitory zinc includes at 
least one residue within the 14 amino acids between 1795 and 1809.  The location of 
these residues within the TcdA1-1832 crystal structure leaves room for the possibility that 
the zinc is coordinated at the interface of the delivery domain and the autoprocessing 
domain, blocking the InsP6 binding site.  A second zinc is coordinated in the APD active 
site and is required for catalytic activity.  Zinc represents a novel regulatory mechanism 
for the enzymatic activity of TcdA in vitro. 
 These data have advanced our understanding of the mechanistic actions of TcdA 
and TcdB but many unanswered questions remain.  These questions and our efforts 
and ideas to investigate them are described in the next section.   
 
Future Directions 
 
What is the molecular target of 0449? 
 Our data suggest that the molecular target of 0449 is upstream of the initial 
calcium release from the endosome.  Also, the similarities between the protective 
effects of bafilomycin A1 and 0449 suggest that 0449 may be targeting a molecule in 
the endosome.  Similarities between the calcium release profiles of 0449 and known T-
type calcium channel inhibitors indicate that an unidentified endosomal T-type calcium 
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channel may be involved in the TcdB induced NOX production of ROS.  This hypothesis 
has been preliminarily supported by the calcium release profiles of siRNA knockdown of 
Tpcn1 and Trpml1, channels associated with endosomes, and Cav3.3, a known T-type 
calcium channel.  
 
How is Ca2+ regulated in the NADPH oxidase (NOX) pathway initiated by TcdB? 
 One of the key discoveries our lab has made regarding the NOX pathway 
induced by TcdB is the importance of calcium release events.  Based on kinetic assays 
investigating calcium release, we have observed a biphasic calcium release in response 
to TcdB.  We consistently see a smaller, transient release early after intoxication 
followed by a much larger, sustained calcium release event.  Inhibitor data combined 
with siRNA knockdown data have led us to hypothesize that upon internalization of 
TcdB, there is a small, localized calcium release from the endosome.  This transient 
calcium burst results in undetermined signaling events that ultimately result in a much 
larger and sustained calcium release from the endoplasmic reticulum (ER).  We 
speculate further that these calcium release events damage the mitochondria, resulting 
in mitochondrial release of ROS.  These events may feed back into the NOX production 
of ROS creating a positive feedback loop that results in aberrant NOX-derived ROS 
production, ultimately leading to necrosis.   
 
 
Figure 5.1.  TcdB 
induces a biphasic 
calcium release from 
cells.  HeLa cells were 
intoxicated were 
intoxicated with 10 nM 
TcdB and incubated at 37 
°C.  Calcium levels were 
assessed using a 
fluorescent calcium 
indicator, Fluoforte, every 
5 minutes for 125 
minutes.  Data points 
represent the average 
relative signal of 3 
experiments performed in 
triplicate. 
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 Calcium release may be the property of TcdB initiated NOX activation that leads 
to the host cell’s demise.  IL-1 and TNF ligation to the cell surface also initiate NOX 
assembly and activation, but the result is low levels of ROS used by the cell as signaling 
molecules.  Interestingly, we cannot detect a calcium release event in response to IL-1 
or TNF treatment of cells in an endpoint assay.  If calcium release is the disease state 
determinant of the NOX pathway, then understanding the mechanism by which calcium 
release occurs from the endosome is crucial to preventing the detrimental effects of 
NOX activation.  Potential calcium channels in the endosome present novel drug targets 
in the treatment of not only CDI, but also other diseases in which aberrant NOX-derived 
ROS has been implicated.  Such diseases include cardiovascular disease, 
neurodegenerative disease, and pancreatitis.   
 
What are the unique properties of the interactions between TcdB and the redoxosome? 
 The redox active endosome, or ‘redoxosome,’ possesses several unique 
qualities that set it apart from normally maturing endosomes, including the regulation of 
ion transport.  We have observed a toxin dependent interaction with the redoxosome 
that regulates the function of the NOX complex.  Several point mutations in the delivery 
domain, spread out over the length of the domain, result in protection of the cell from 
necrosis.  We do not detect any necrotic markers, calcium release, ROS production, or 
LDH release, in cells intoxicated with the delivery domain mutants tested.  This 
phenotype is independent of pore formation, as the mutants have varying capabilities in 
forming pores as judged by rubidium release from liposomes and Rac1 glucosylation 
assays in cells.  We hypothesize that the delivery domain of the TcdB interacts with 
some component of the redoxosome, such as the membrane, an ion channel, or 
another protein, that is important for proper function of the NOX complex.  Dr. Fred 
Lamb, at Vanderbilt, has the capability to purify redoxosomes and investigate their 
unique components, such as associated proteins, ion channels, and lipids.  We are 
hopeful that this collaboration will provide insight into the important interactions between 
TcdB and the redox active endosome. 
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How does TcdB-induced apoptosis contribute to pathogenesis? 
 We clearly detected TcdB-induced apoptosis in YAMC cells at concentrations 
lower than 100 pM.  It remains unclear what the concentration of toxin is in the colon at 
the site of infection.  Unfortunately, we cannot detect TcdB induced damage in our 
colonic explants model at concentrations where apoptosis is observed.  It is possible 
that the absence of a damage phenotype is the result of the 5 hour time point used in 
our model system.  The shorter time points are used, in part, to ensure the tissue 
remains healthy.  Longer time points have resulted in damaged untreated tissue.  We 
are collaborating with Frank McKeon’s lab who has developed a system by which they 
can grow colonic tissue from human stem cells (manuscript under review at Nature).  
This very exciting new model system allows us to investigate the effects of lower 
concentrations of toxin at much longer time points post-intoxication.  It may also be 
possible to develop an infection model in this system. Data from this model could 
potentially help to determine the concentration of toxin that is necessary to induce 
colonic damage and the respective mechanism that should be targeted to prevent 
damage from occurring. 
 
Can we identify small molecule inhibitors of TcdA? 
 Now that we can detect TcdA-induced cell death in YAMC cells, a convenient 
model system that recapitulates what we observe in our tissue explant model, we can 
conduct a high throughput screen for compounds that protect cells from TcdA-induced 
cell death.  The screen could be conducted in a manner similar to the screen against 
TcdB in which the readout for the assay is cell death.  It is reasonable to expect to 
identify hits that are inhibitors of the GT activity of TcdA, as we have clearly observed a 
GT-dependent apoptotic cell death in response to TcdA intoxication.  If the endpoint of 
the primary assay is cell death, it is equally reasonable to expect to find compounds that 
inhibit other steps of the intoxication mechanism that are thought to be required for cell 
death including host cell receptor binding, translocation, and autoprocessing activities.  
While the development of secondary assays identifying compounds that interact with 
the toxin directly may be more straight-forward, molecules that effect events 
downstream of GTPase glucosylation are also potential hits.  Compounds that inhibit 
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TcdA-induced cell death are needed both as investigational tools and as candidates for 
novel therapeutics.  Probes that can help define the downstream events that lead to 
apoptosis after GTPase modification could prove useful in understanding disease 
pathogenesis as a whole.  Also, it is likely that targeting both cell death mechanisms, 
necrosis and apoptosis, will be necessary to effectively combat CDI in a toxin-centric 
therapeutic strategy.  
 
Which residues in TcdA are coordinating the inhibitory zinc? 
 The residues that coordinate the inhibitory zinc remain unclear.  Based on 
autoprocessing assays with the C-terminal truncations, we have narrowed possible 
residues to the 14 amino acids between 1795 and 1809.  There are four acidic residues 
capable of coordinating a zinc ion at positions 1803, 1805, 1807, and 1809.  Single 
point mutation of these residues did not have an impact on autoprocessing activity; all 
mutants still required EDTA to induce cleavage.  It is possible that double mutants will 
be more informative.  Also, these residues are located at the interface of the delivery 
domain and the APD.  It is possible that the zinc is coordinated by residues in the APD 
as well.  Point mutations have been made at residues E572, E573, E646, and E694 and 
will be investigated for autoprocessing activity in the absence of EDTA.  Alternatively, 
we can attempt to find other crystallization conditions favorable for the inhibitory zinc to 
remain coordinated.  Efforts to crystallize TcdA holotoxin could also pursued.  The 
identification of the residues coordinating the zinc could be useful in determining the 
functional importance of this regulatory mechanism in the cell death pathway induced by 
TcdA.   
 
Can we create a zinc binding site in TcdB? 
 Once we have identified the inhibitory zinc binding site, we would wonder if we 
could create a zinc binding site in TcdB by site-directed mutagenesis.  If we did create a 
zinc binding site, and thereby creating an artificial regulatory mechanism, we would be 
very interested in the effects it would have on the intoxication and cell death 
mechanisms induced by TcdB.  Would the presence of the inhibitory zinc make the 
apoptotic mechanism of cell death more prominent if there was tighter regulation of 
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translocation and autoprocessing?  Would the inhibitory zinc affect the necrotic 
mechanism of cell death induced by TcdB? 
 
What is the functional significance of the inhibitory zinc in cellular intoxication? 
We hypothesized that the inhibitory zinc was, at least in part, stabilizing the 
neutral pH conformation and regulating the environment in which TcdA undergoes 
autocatalytic cleavage.  To test this, cells were pretreated with known endosomal 
acidification inhibitors, bafilomycin A1, NH4Cl, or mock conditions, and then intoxicated 
with TcdA or TcdB.  The cells were lysed and Rac1 modification was assessed, using 
an antibody sensitive to unmodified Rac1 only, as a measure of toxin conformational 
change, pore formation, and GTD translocation.  The glucosyltransferase mutants, 
TcdA D285/287N and TcdB D286/288N, were used as negative controls, as they should 
not modify Rac1.  In cells pretreated with bafilomycin or NH4Cl, subsequent intoxication 
with TcdA resulted in significantly less Rac1 glucosylation compared to the cells treated 
with toxin only.  The lack of Rac1 modification when endosomal maturation is inhibited 
suggests that low pH of the endosome is required for the release of the inhibitory zinc 
and the conformational change necessary for translocation of the GTD.  When cells 
were intoxicated with TcdB after bafilomycin or NH4Cl pretreatment, however, there was 
no inhibition of Rac1 modification.  This result suggests that the low pH of the mature 
endosome is less essential for TcdB translocation.  One major difference between TcdA 
and TcdB is the presence of the inhibitory zinc in TcdA, which can be released upon 
exposure to low pH.  These data suggest that the zinc is an important regulator of the 
pH dependent conformational change that promotes autoprocessing activity of TcdA in 
cells.  We expect to be able to better delineate the specific functions of the inhibitory 
zinc once we have identified the coordination site of the inhibitory zinc and can 
construct point mutations.   
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What is the autoprocessing catalytic mechanism of action? 
 We have discovered that the catalytic mechanism of the APD is not that of a 
cysteine protease, but is rather a zinc-dependent protease.  We hypothesize that 
His759 sterically hinders the substrate binding the active site until InsP6 binds.  As the 
allostery is communicated through the β-flap, and His759 is pulled out of the active site, 
the substrate is then able to bind.  Based on previous structures and our own 
preliminary structure, we further hypothesize that the substrate lies between two zinc 
coordinating residues, Cys700 and His655.  This suggests that upon substrate binding, 
a new zinc coordination site is created.  It is in this site that catalysis occurs.  
Unfortunately, we have no insight into the conformation or residues involved in this 
active site.  We can speculate and propose possible coordination sites based on 
structural data.  We have mutated Glu745 and Trp763 to test for defects in 
autoprocessing activity.  Ideally, however, we will be able to determine the structure of 
substrate bound state with the zinc bound in the active site.  We are actively pursuing 
this structure with a non-cleavable mutant, L542A, however, crystal trials have been 
unsuccessful thus far.  We also plan to try to crystallize the protein in the presence of an 
active site peptide mimetic.  Determining the mechanism by which autoprocessing 
occurs may help to guide therapeutic development. 
 
 
Figure 5.2.  The inhibitory zinc 
may regulate pH dependent 
GTD translocation.  HeLa cells 
were preincubated with 10 nM 
bafilomycin, 10 mM NH4Cl, or 
mock for 1 hour at 37 °C.  Cells 
were then intoxicated with 10 nM 
toxin and incubated at 37 °C for 
with 1 or 3 hours (TcdB toxins or 
TcdA toxins, respectively).  Cells 
were lysed as described 
previously, and lysates were 
probed for unmodified and total 
Rac1 as previously described. 
93 
 
 
 
Can we test our hypotheses in a mouse model? 
 In collaboration with Dr. David Aronoff, we are beginning to test our hypotheses 
in a mouse infection model.  Thus far, we can observe colonic tissue damage in mice 
treated with antibiotics prior to infection with spores from the 10643 strain of C. difficile.  
This is a laboratory strain that is known to produce high levels of toxin.  We have 
preliminary data with NOX1 knockout mice infected with the 10643 strain that show 
significantly less colonic damage compared to control mice.  This data suggests that the 
NOX pathway induced by TcdB intoxication of tissue culture cells is relevant in 
pathogenesis.  We would also like to conduct experiments testing our hypothesis 
surrounding mechanistic differences between TcdA and TcdB and the importance of 
toxin regulation in the context of disease.  In the future, we would like to create 
genetically altered C. difficile strains in which we can make single point mutations within 
toxin genes.  This is possible using the newly developed ClosTron technology, though 
attempts by other groups at inserting single point mutations have not yet been 
successful.  Single gene knockouts of each of the toxins, TcdA and TcdB, have been 
Figure 5.3.  The TcdA 
APD substrate may lie 
between Cys700 and 
His655.  The structures of 
TcdA homologues, A, 
VcRTx C3568S [1] and B, 
TcdB-As-OSL [3] suggest 
that the substrate lies 
between the catalytic Cys 
and His residues.  These 
structures further suggest 
that the catalytic 
mechanism is unusual. 
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successful, however, and we are collaborating with Dr. Dena Lyras who has isogenic 
knockout strains from an epidemic strain, M7404.  We intend to exploit this technology 
to gain further insight into the relative functional contributions each of each toxin in 
disease.   
 Our goal is to understand the functional relevance of each toxin and the 
respective mechanisms they employ cause disease.  The data presented here suggest 
that TcdA and TcdB initiate distinctly different mechanisms of cell death in cell culture 
and colonic explant models.  Our compound, 0449, and use of chemical chelators have 
been useful tools in beginning to delineate differences between the mechanistic actions 
of the toxins.  Moving into an infection model with 0449 and genetically modified strains 
of C. difficile will provide even more insight into disease pathogenesis. 
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APPENDIX I 
 
 
Small molecule inhibition of TcdB induced necrosis 
 
 
Successful treatment of CDI has proven to be a difficult task with recurrence and 
death rates continuing to increase. The medical challenge highlights the need for more 
effective therapeutics.  Antibiotics are the standard course of treatment, but they have 
been shown to further disrupt the intestinal microbiota.  While the immediate C. difficile 
infection may clear, antibiotic therapy may contribute to high recurrence rates.  A novel 
therapeutic strategy has been put forth in which the toxins, TcdA and TcdB, are the 
targets of new drugs.  CDI is a toxin mediated disease, and it is thought that preventing 
colonic damage by inhibiting the function of the toxins would provide the patient a 
window of opportunity to more effectively clear the infection, potentially reducing the risk 
of recurrence.   
We performed a high throughput screen of 16,000 compounds in the Vanderbilt 
University High Throughput Screening Faciility using a robust cell viability assay (Z’ = 
0.8) to assess protection of Chinese Hamster Ovary (CHO) cells from TcdB induced cell 
death (Figure A1.1).  CellTiterGlo, used as our screen assay readout, is a luminescent 
viability indicator that detects ATP in cells.  Because our assay was a cell based assay 
involving the entire mechanism of intoxication, we thought it possible to identify 
compounds that not only inhibited TcdB directly, but that also inhibited host cell factors 
important in the death pathway.  We wanted to focus on those compounds that inhibited 
the toxin directly, however, and began designing secondary assays to identify specific 
inhibitors of TcdB function.  We recognized that any functional domain could potentially 
be inhibited, including host cell receptor binding, delivery, autoprocessing, or 
glucosyltransfer.  Because the APD and GTD were thought to be required for TcdB 
induced cell death and contain defined active and allosteric binding sites, we anticipated 
identifying a number of compounds inhibiting these enzymatic activities. 
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We identified 176 hits that conferred protection against TcdB-induced 
cytotoxicity.  Upon discovering autoprocessing and glucosyltransferase activities were 
not required for TcdB-induced necrosis, however, we no longer had a mechanistic 
context for understanding how these molecules were working. Once we discovered that 
TcdB activates the host NADPH oxidase (NOX) complex, resulting in aberrant 
production of reactive oxygen species (ROS) and necrosis in epithelial cells, we were 
able to return to the hits identified in our small molecule inhibitor screen and reevaluate 
how they might be conferring protection.   
We were encouraged to find 16 compounds containing phenols or free thiols, 
capable of scavenging ROS.  While these compounds are a satisfying confirmation for 
both our proposed mechanism of ROS dependent necrosis and our assay, we were not 
Figure A1.1.  High-throughput screen to identify small molecule inhibitors 
of TcdB.   Cells were pretreated with inhibitor at 37 °C for 1 h, intoxicated with 
10 nM TcdB, and incubated at 37 °C for 6 h.  Cell viability was measured using 
CellTiterGlo.  A representative plate from the screen is shown with toxin and 
untreated controls in columns 1 and 2, respectively, which were used to calculate 
the Z’ of each plate (Z’ = 0.8).  The bar in column 23 represents 3 standard 
deviations from the mean of the plate.  Any compound protecting cells from 
TcdB-induced cell death more than 3 standard deviations from the mean was 
considered a hit.  176 hits were pulled and confirmed from a 16,000 compound 
screen.  The 176 confirmed hits were classified into 3 groups: scavengers, non-
scavengers, and dihydropyridines, based on their chemical structures.  
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interested in pursuing scavengers as therapeutics or mechanistic probes.  Thus far, we 
have separated the hits into three categories based on their chemical properties: 
scavengers (16 compounds), non-scavengers (109 compounds), and dihydropyridines 
(51 compounds).  The non-scavenger group of compounds is very chemically diverse.  
We would be very interested to find compounds that inhibit the assembly and activation 
of NOX.  Assays to determine successful assembly of NOX to test the non-scavenging 
group are being optimized now.  The dihydropyridine (DHP) scaffold has the potential to 
inhibit the pathogenic mechanism both as a scavenger of ROS and as a calcium 
channel inhibitor.  Several DHP compounds used to treat hypertension, such as 
nifedipine, act by blocking calcium channels (Figure A1.2A).  Together with siRNA 
knockdown data acquired by Dr. Melissa Farrow, this observation led us to investigate 
how calcium functions in NOX-dependent necrosis induced by TcdB and how our DHP 
scaffold is involved in protection.   
 
 
 
 
 
 
 
We decided to focus our studies on compound 0449 (Figure A1.2B), one of the 
most protective DHP compounds, and compare its inhibitory properties to those of 
nifedipine, defined as an L-type calcium channel inhibitor.  First, we compared the 
protective effects of 0449 and nifedipine in a cell viability assay.  As shown in Figure 
A1.3A, 0449 protects cells from TcdB induced necrosis more effectively and at lower 
concentrations than nifedipine.  We observed a similar phenotype in our ROS assay.   
Figure A1.2.  Chemical structures of 
dihydropyridines.  A, Nifedipine, commonly 
prescribed to treat hypertension, is a known L-
type calcium channel inhibitor.  B, 0449 was a top 
hit from our small molecule inhibitor screen. 
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Both compounds provide reasonable inhibition of ROS production, though 0449 
prevents the production of ROS at lower concentrations than nifedipine (Figure A1.3B).  
We next wanted to investigate whether TcdB induced a calcium response in the cell.  
We can detect a robust calcium release in response to TcdB intoxication, comparable to 
Figure A1.3.  Nifedipine and 0449 prevent 
TcdB induced necrosis, ROS production, 
and calcium release.  Cells were pretreated 
with inhibitor at 37 °C for 1 h, and then 
intoxicated with 10 nM TcdB and incubated at 
37 °C overnight.  A, Cell viability was 
measured using CellTiterGlo.  B, ROS 
production and C, calcium release were 
measured using fluorescent indicators.  The 
data in each graph represent the average of 
three experiments in which each condition 
was tested in triplicate.  Error bars represent 
the standard deviation between experiments. 
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that of ionomycin, a known ionophore (Figure A1.3C).  0449 inhibits the calcium release 
down to background cellular calcium levels at sub-micromolar concentrations of 
compound.  Notably, nifedipine did not significantly inhibit the calcium release initiated 
by TcdB intoxication (Figure A1.3C).  These data confirm that 0449 is an excellent 
inhibitor of TcdB-induced necrosis and is capable of directly or indirectly blocking TcdB 
induced calcium responses.   
 
 
 
The superiority of 0449 inhibition of calcium release compared to nifedipine 
seemed curious to us.  We thought it possible that 0449 is a more potent inhibitor of L-
type calcium channels and wondered how it would compare to other, structurally diverse 
L-type calcium channels.  In Figure A1.4A, calcium release data indicate that 0449 is 
more potent than all other L-type calcium channel inhibitors, leaving room for the 
possibility that the target of 0449 is not an L-type calcium channel.  To test this, we 
compared 0449 to mibefradil, a T-type calcium channel inhibitor.  Our preliminary data 
Figure A1.4.  0449 inhibits TcdB 
induced calcium release more 
similarly to T-type calcium channel 
inhibitors.  A, Comparison of 0449 to 
structurally diverse L-type calcium 
channel inhibitors.  Bafilomycin is a V-
ATPase inhibitor.  B, Comparison of 
0449 to a T-type calcium channel 
inhibitor, mibefradil. 
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show mibefradil inhibits TcdB induced calcium release to levels comparable to the 
inhibition of 0449 (Figure A1.4B).  Though DHPs are known to inhibit L-type calcium 
channels, these data suggest that 0449 may inhibit a T-type calcium channel.  These 
studies are in very early stages and require further investigation. 
Interestingly, bafilomycin A1 inhibits calcium release in response to TcdB to 
levels comparable to 0449 (Figure A1.4).  This suggests that the target of 0449 might 
reside in the endosome.  We are in the preliminary stages of understanding the ion 
regulation of redox active endosomes and the channels that are involved.  Dr. Melissa 
Farrow has identified, by siRNA knockdown, several endosomal ion channels that are 
important in TcdB induced necrosis.  Our preliminary studies on both endosomal ion 
channels and the importance of calcium in the TcdB induced NOX pathway are 
discussed further in Chapter V. 
 
 
 
 
 
 
We also tested the efficacy of 0449 in our colonic explant model.  When we 
pretreated porcine colonic explants with 5 μM compound, the tissue was protected from 
TcdB induced damage (Figure A1.5A).  Pathology scores demonstrated no significant 
difference between tissue that was treated with 0449 alone and tissue treated with 0449 
and TcdB (Figure A1.5B).  These data suggest that in addition to protecting cells from 
Figure A1.5.  0449 prevents TcdB induced tissue damage.  Porcine colonic explants were 
mock or pretreated with 5 uM compound for 1 h at 37 °C and then intoxicated with 10 nM TcdB 
and incubated at 37 °C for 4 h.  A, The tissue was fixed, and sections were stained with H&E.  B, 
Pathology scores based on a semi-quantitative injury scoring system.  Statistics were performed 
in Excel using a paired, two-tailed student’s t-test. 
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TcdB induced damage, 0449 also provides protection from the effects of TcdB in the 
context of colonic tissue.  We are encouraged by these data and we look forward to 
moving into a mouse infection model in the future. 
 
Methods 
 
Small molecule inhibitor screen 
 Compounds (final concentration of 10 μM) were put into 384 well plates using the 
VU HTS facility’s robotic technology.  CHO cells were seeded into the screen plates and 
incubated at 37 °C for 1 hour.  Cells were then intoxicated with 30 nM TcdB and 
incubated at 37 °C for 6 hours.  Viability of the cells was assessed using CellTiterGlo 
(Promega) as previously described.  When analyzing the viability data, the Z’ score of 
each plate was calculated and the average luminescence signal of each plate was 
calculated.  A compound was considered a ‘hit’ if the signal from cells treated with that 
compound was more than 3 standard deviations above the average signal of the plate.   
 
Viability, ROS, and Calcium assays 
 Viability and ROS assays were performed as previously described.  For calcium 
assays, HeLa cells were preincubated with inhibitor for 1 hour at 37 °C.  Cells were then 
intoxicated with 10 nM TcdB and FluorForte (Enzo) calcium indicator was used 
according to manufacturer’s instructions. 
 
Colonic explants 
 Colonic explants were prepared as previously described , and preincubated with 
with 5 μM 0449 or an equal volume of solvent at 37 °C for 1 hour.  Explants were then 
intoxicated with either 10 nM TcdB or an equal volume of buffer and incubated at 37 °C 
for 5 hours.  Tissue was fixed, prepared, and scored as previously described.  Statistics 
were performed in Excel with a paired, two-tailed student’s t-test. 
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